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Advances in cancer treatments have increased the overall five-year survival rate 
for children and adolescents with cancer to almost 85% (Howlader et al., 2014). 
However, the use of intensive treatment modalities to improve survival rates has 
jeopardized health-related quality of life (HRQOL) of survivors of childhood cancer.  
Survivors of childhood cancers are likely to experience serious or life-threatening late 
effects (Berk & Meyers, 2015) which can continue into adulthood (Bassal, 2006; 
Oeffinger et al., 2006). Late effects refer to various health problems in physical, mental, 
and social domains that occur after completion of cancer treatment (National Cancer 
Institute, 2016). Several studies of adults with cancer have identified associations 
between symptom clusters and poor patient outcomes, typically HRQOL (Dodd, 
Miaskowski, & Paul, 2001a; Kim, Barsevick, Beck, & Dudley, 2012; Miaskowski et al., 
2006). There are few studies, however, examining the relationship of symptom clusters 
and HRQOL in survivors of childhood cancer.  
The purpose of this study was to examine the impact of late effects on HRQOL in 
survivors of childhood cancer. This project investigates the association between subgroup 
membership based on the impact of late effects on HRQOL using cluster mixture 
modeling. The revised Dynamic Symptoms Model (Brant, Dudley, Beck, & Miaskowski, 
2016) was used as a theoretical framework, which is focused on the relationship between 
predictors and symptom experience. St. Jude Lifetime Cohort (SJLIFE) study data were 
used for this analysis. The study participants were diagnosed with childhood cancer and 
  
 
 
were treated between 1962 and 2002 at the St. Jude Children’s Research Hospital; 3,129 
participants were eligible for this study.  
 Using mixture modeling, a person-centered approach was used. The participants 
were young adult survivors (the mean age at the time of the survey was 31.0 years), were 
diagnosed with cancer during childhood (mean age of cancer diagnosis was 8.45 years), 
and were long-term survivors (mean time since cancer diagnosis was 28.10 years). 
Participants had various types of cancer including leukemia, lymphoma, sarcoma, and 
central nervous system tumors. Two distinctive subgroups were identified: the “high 
symptom cluster” group and the “low symptom cluster” group. Among all participants, 
pain was the most prevalent symptom (75.5%), and disfigurement (55%) and sensation 
abnormalities (31.1%) were higher. Several variables were associated with the high 
symptom cluster. Participants who were more than 40 years old at the time of the survey, 
female, non-Hispanic white, had less education, were unmarried, and had lower annual 
income were more likely to be in the high symptom cluster group. Participants who were 
in the high symptom cluster group reported lower physical and psychosocial HRQOL 
compared to those in the low symptom cluster group. Several socioeconomic and clinical 
variables affected HRQOL among participants in this study. In particular, use of certain 
types of chemotherapy (e.g., cisplatin, carboplatin, or oxaliplatin) was associated with 
poorer physical HRQOL and better psychosocial HRQOL.  
 The current study identified symptom cluster groups among young adult survivors 
of childhood cancers and found meaningful predictors that affect symptom cluster 
membership and HRQOL outcomes. The findings of this study provide information for 
  
 
 
health care providers regarding treatment effects and subsequent HRQOL in children 
with cancer. These findings could be used as a basis for designing an intervention for 
individuals in the high symptom cluster group. Future research should include children 
with cancer who are in the various survivorship periods in order to better understand the 
relationships between symptom clusters and HRQOL across time.  
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CHAPTER I 
INTRODUCTION 
 
 
Advances in cancer treatments have increased the overall five-year survival rate 
in the U.S. for children and adolescents with cancer to almost 85% (Surveillance, 
Epidemiology, and End Results Program, 2010). For example, the five-year survival rate 
for leukemia, the most common type of cancer in children and adolescents, was 48% in 
the years 1975 to 1979, but increased to 84% during the years 2003 to 2009 (Ward, 
DeSantis, Robbins, Kohler, & Jemal, 2014). These remarkable improvements have 
spurred interest in health-related quality of life (HRQOL) of childhood cancer survivors. 
Children and adolescents view life differently than adults because they are in different 
developmental periods, so it is important to understand what quality of life (QOL) means 
from their perspective (Clarke & Eiser, 2004).  
Researchers have examined the prevalence of symptoms or the associations 
between symptoms and HRQOL in survivors of adolescent cancer (Fernandez-Pineda et 
al., 2016; Huang et al., 2013; Maurice-Stam, Oort, Last, & Grootenhuis, 2009). Most of 
the literature reports that survivors of childhood and adolescent cancer have had similar 
or better QOL than healthy control groups. However, subgroups of survivors report 
significant psychological distress and poor QOL (Maunsell, Pogany, Barrera, Shaw, & 
Speechley, 2006; Zeltzer et al., 2008). Adolescent and young adult survivors of childhood 
cancer are affected by several factors known to reduce QOL, including late effects, low     
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income, type of cancer, and gender. Female survivors of childhood cancer and adolescent 
cancer reported lower QOL than male survivors (Maunsell et al., 2006; Zebrack, Yi, 
Petersen, & Ganz, 2008). Thus, identifying factors related to QOL in survivors of 
childhood cancer is important in order to help them make effective survivorship plans 
and achieve optimum health and wellness (Lipscomb, Gotay, & Snyder, 2007). To 
achieve these goals, data were obtained from the St. Jude Life Cohort Study (SJLIFE). 
The SJLIFE data were collected from St. Jude Children’s Research Hospital and included 
a large sample size and various variables and health outcomes of childhood cancer 
survivors, making it an ideal choice for examining these important issues.  
Cancer Diagnosis during Childhood and Adolescence 
During adolescence, an individual establishes a personal identity, peer 
relationships and family roles (Mavrides & Pao, 2014). Cancer diagnosis during 
adolescence is a substantial stressor affecting typical development (Ramini, Brown, & 
Buckner, 2008). Adolescence is a critical developmental period, so cancer diagnosis 
during this period can have significant psychosocial impacts during and after cancer 
treatment. These psychosocial impacts include symptoms of depression, anxiety, post-
traumatic stress disorder, distorted self-image, lower self-esteem, and limited social 
relationships (Essen, Enskär, Kreuger, Larsson, & Sjödén, 2000; Hewitt, Weiner, & 
Simone, 2003; Panel & Reuben, 2004; Seitz et al., 2010; Zebrack & Chesler, 2001). In 
order to understand cancer effects during adolescence, and how these effects might be 
manifested later in life, examining nationwide, longitudinal data can be useful. The 
National Cancer Institute (NCI) funded a nationwide study in the U.S for childhood 
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cancer survivors. The project, called the Childhood Cancer Survivors Study (CCSS), is a 
26-institution retrospective cohort study including more than 14,000 childhood cancer 
survivors who were diagnosed between 1970 and 1986, and includes 4,000 of their 
siblings as a control group (Robison et al., 2009). Several researchers have used CCSS 
data and found that survivors experienced late effects, psychological symptoms, activity 
limitations, and functional impairments compared to healthy siblings (Fernandez-Pineda 
et al., 2016; Florin et al., 2007; Huang et al., 2013; Hudson et al., 2013). In particular, 
more than 75% of survivors reported at least one late effect, including physical symptoms 
such as organ damage, obesity, pain, learning problems and secondary cancer (Huang et 
al., 2013; Hudson et al., 2013). These late effects could affect survivors’ HRQOL.  
Also, children or adolescents who are diagnosed with cancer need to stay at the 
hospital where their treatment protocol is based, with stays ranging from several months 
to a year, which can cause isolation from their peers or school, preventing them from 
feeling like a “normal” child or adolescent. These survivors, who navigate several 
developmental tasks during adolescence, might have difficulty forming social 
relationships, social identity, and achieving physical and cognitive maturation compared 
to “normal” adolescents (Hudson et al., 2003; Woodgate, 1999). Adolescent cancer 
survivors report that being independent from their parents is difficult since their parents 
become overprotective of them after cancer diagnosis (Hokkanen, Eriksson, Ahonen, & 
Salantera, 2004). Moving toward independence from parents during adolescence is a 
typical developmental task of this period. 
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Social support could aid in coping with a cancer diagnosis and treatment in 
children with cancer. In particular, mothers and peers play an important role (Haluska, 
Jessee, & Nagy, 2002; Kyngäs et al., 2001; Woodgate, 2006). Previously known friends, 
who were friends before children or adolescents were diagnosed with cancer, can give 
greater social support than friends who are made after cancer diagnosis (Woodgate, 
2006). This might be because close peers play a role as “shield-peers” when adolescents 
who have cancer participate in a friends’ gathering. The cancer survivors might have 
concerns when comments about their changed appearances are voiced (Larouche & Chin-
Peuckert, 2006).  
Adolescence is a period during which individuals experience rapid physical, 
cognitive, and psychosocial changes (Kim, Koh, & Leventhal, 2005). Adolescents can 
better understand their prognosis, treatment, and complications than children who have 
experienced cancer. During adolescence, cognitive abilities transform from concrete 
operations to formal operations (Inhelder, 1958). Having formal operational functions 
helps adolescents think abstractly and better understand their treatments and possible 
complications. This advanced cognitive development in adolescents may engender more 
anxiety or worry about cancer treatment, complications, and prognosis than would be 
seen in younger children.  
Several studies using the Childhood Cancer Survivor Study (CCSS) and the St. 
Jude Lifetime Cohort (SJLIFE) study data have made significant contributions to the 
childhood cancer survivorship literature for those between 0 and 19 years old at the time 
of their cancer diagnosis (Huang et al., 2013; Hudson et al., 2013; Ness et al., 2013). 
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Unlike adult cancer patients, survivorship plans for children and adolescent cancer 
patients need to address unique developmental tasks. Through the current study, 
subgroups of survivors of childhood cancer will be identified taking into account 
developmental characteristics, predictors, and consequences of subgroup membership.  
Individualized survivorship plans, focused on the unique challenges and needs of those 
surviving childhood cancer, have the potential to improve quality of life for these 
individuals.  
Definitions of Survivors of Childhood Cancer  
 There are various definitions for survivors of childhood cancer. Researchers have 
used “young adult survivors of childhood cancer” (Oeffinger et al., 2004; Zebrack, 
Casillas, Nohr, Adams, & Zeltzer, 2004), “adolescent and young adult survivors of 
childhood cancer” (Nathan et al., 2013), “adolescent survivors of childhood cancer” 
(Brinkman et al., 2016), and “survivors of childhood and adolescent cancer” (Mertens et 
al., 2001; Mulrooney et al., 2009). In 2005-2006, the National Cancer Institute (NCI) 
addressed survivors of childhood cancer care needs, and identified their cancer 
characteristics and outcomes of treatment. Many researchers use the definition of 
adolescent and young adult (AYA) patients as those who were diagnosed with cancer 
between 15 and 39 years of age. However, this age group includes various types of 
cancer that may often occur in adults as well as adolescents and children. The types of 
cancer are different based on an individual’s age of cancer diagnosis; for example, the 
broader age range, extending to 39 years old, includes breast cancer, thyroid cancer, 
cervical sarcoma, and colorectal carcinoma, common types of cancer for adults (Bleyer, 
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2007). Acute lymphoblastic leukemia, brain and central nervous system (CNS) tumors, 
neuroblastoma, and non-Hodgkin’s lymphoma are the most common in children, whereas 
Hodgkin’s lymphoma, thyroid carcinoma, brain and CNS tumors, and testicular germ cell 
tumors are most common in adolescents. Common in both children and adolescents are 
non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphocytic leukemia, and bone 
tumors (Ward et al., 2014).  
Late effects and treatment effects might be different based on type of cancer or 
type of treatment. Thus, it is important to make distinction between different types of 
cancer based on an individual’s age. The Surveillance, Epidemiology, and End Results 
(SEER) program by NCI defined AYAs as between 15 and 29 years of age because those 
in this age group have similar biological characteristics. Also, adolescents and adults 
have different developmental tasks. When survivorship plans are made, it is better to base 
plans on the unique developmental needs of the individual. Thus, in defining those who 
were diagnosed during childhood, it is important to consider the age range of persons in 
that category based on epidemiological findings as well as developmental characteristics.  
Key terms for the current study were defined.  
1) Survivor:  In 1986, the National Coalition for Cancer Survivorship (NCCS) 
used the term “survivors,” because at that time cancer was considered a disease to fight. 
In 2006, the same institution defined the term as a person who had been free of cancer for 
five years, or someone who was living with cancer (Rowland, Hewitt, & Ganz, 2006). 
Moreover, NCI used a broader concept of survivor: “An individual is considered a cancer 
survivor from the time of diagnosis, through the balance of his or her life. Family 
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members, friends, and caregivers are also impacted by the survivorship experience and 
are therefore included in this definition” (NCI website, Office of Cancer Survivorship, 
2016). The definition offered by NCI, which includes a broad period from cancer 
diagnosis to the end of life, was chosen for this research. Cancer diagnosis during 
childhood might bring dramatic life changes, and the impact persists even after 
completion of treatment. In addition, survivors of childhood cancer often have a long life 
after completion of cancer treatment. When clinicians consider survivorship care plans 
for survivors of childhood cancer, it is necessary to consider the survivors’ lives after 
treatment.  
2) Survivors of childhood cancer: Survivors of childhood cancer are defined as 
those who are diagnosed with childhood-specific cancers and both undergoing cancer 
treatment or after cancer treatment is complete. In this current study, the term “survivors 
of childhood cancer” refers to individuals who were diagnosed with cancer when less 
than 19 years old. Using SJLIFE data, the focus of this study is on survivors between 0 
and 19 years old.   
3) Late effects: Late effects refer to various health problems including physical, 
mental, and social aspects of these problems that occur after cancer diagnosis or after 
completion of cancer treatment. These may be associated with cancer or cancer treatment 
(NCI, 2016). In this study, symptoms or complications of treatment are interchangeably 
used with the term “late effects.”  
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Late Effects after Cancer Treatment  
Survivors of childhood cancer have experienced a serious, life-threatening 
disease, and the late effects of their cancer treatment can continue into adulthood (Bassal, 
2006; Berk & Meyers, 2015; Oeffinger et al., 2006). The reported late effects include 
various symptoms such as fatigue and pain, psychological symptoms, and 
cognitive/memory loss (Arpawong, Oland, Milam, Ruccione, & Meeske, 2013; Larsson, 
Mattsson, & von Essen, 2010; Meeske, Patel, Palmer, Nelson, & Parow, 2007). 
According to the SJLIFE study, long-term survivors of childhood cancer suffer from one 
or more symptoms including pain, cardiac and pulmonary symptoms, learning/memory 
problems, anxiety, depression, and/or somatization (Huang et al., 2013). In this current 
study, the impact of late effects of cancer and cancer treatments on HRQOL in survivors 
of childhood cancer were examined. The late effect(s) or symptom(s) present as single or 
together. A symptom is defined as a subjective experience about changes in body 
functioning, sensation, or cognition (Harver & Mahler, 1990). Symptom clusters are 
defined as two or more related symptoms occurring concurrently, particularly when 
symptoms are statistically presented together in a group (Barsevick, 2007; Barsevick, 
Whitmer, Nail, Beck, & Dudley, 2006b; Kim et al., 2012).    
Cancer Survivorships and Health-Related Quality of Life (HRQOL)  
Considering the role of HRQOL in cancer survivorship is important. In the 
literature, researchers use QOL and HRQOL interchangeably (Arpawong et al., 2013; 
Huang et al., 2013; Larsson et al., 2010). Cancer survivorship is a broad concept that 
includes quality of life. The NCI (2016) emphasized that cancer survivorship research 
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should incorporate the physical, psychosocial, and economic conditions of survivors after 
cancer diagnosis and treatments, and it needs to focus on health and life beyond cancer 
diagnosis and treatments. It also seeks to both prevent and control adverse health 
outcomes, such as having poorer HRQOL or secondary malignancies. The “Healthy 
People” series provides ten years of national objectives in order to improve health of all 
Americans. Healthy People 2020 has a goal to increase the mental and physical HRQOL 
among cancer survivors (content C-14) (Healthy People, n.d.). In addition, the Children’s 
Oncology Group (2013) has long-term follow-up guidelines for survivors of childhood 
and adolescent cancer. Although the guidelines consider issues regarding physical and 
emotional complications after cancer treatment, they do not provide any practical 
guidelines to measure QOL of survivors. Similarly, the Institute of Medicine (2007) 
suggested that QOL issues should be addressed in survivorship plans for survivors of 
adult cancer, yet practical guidelines are not employed. With consistent changes to the 
definition of HRQOL across time or based on the process of cancer treatment, it is 
important to regularly assess HRQOL for children with cancer (ranging in age from birth 
to 19 years old).  
Symptom Clusters and Person-Centered Approaches  
There have been few studies using symptoms clusters among survivors of 
childhood cancer. A few studies on adults with cancer have identified an association 
between experiencing symptom clusters and poor patient outcomes (Barsevick et al., 
2006a; Dodd et al., 2001a; Kim et al., 2012; Miaskowski et al., 2006). Some symptom 
clusters identified in adults with cancer might be similar to the clusters identified among 
  
10 
 
survivors of childhood cancer. In order to understand the characteristics and the effects of 
symptom clusters on health outcomes among survivors of childhood cancer, several 
studies of symptom clusters in adults with cancer were reviewed. For example, Kim and 
colleagues used the effects of symptom clusters on health outcomes in adults with cancer 
patients (Kim et al., 2012). Patients reported various symptoms including pain, depressed 
mood, cognitive disturbance, fatigue, and insomnia, both while undergoing and after 
cancer treatment. These symptoms were divided into four groups including “all low 
symptoms,” “high fatigue” and “low pain,” “high pain,” and “all high symptoms.” Each 
subgroup showed differences in health outcomes such as physical performance and 
symptom burden. Patients in the “high symptoms” group showed the lowest physical 
performance across time. This finding is applicable for providing information to design 
interventions for the most vulnerable of groups that has all high symptoms. In addition, it 
is expected that survivors of childhood cancer might have several types of symptom 
cluster groups.   
The majority of studies of adults with cancer have employed traditional variable-
centered approaches such as factor analysis, correlation, and regression. These variable-
centered approaches focus on patients’ symptoms such as the identification of a 
pulmonary symptom group and a pain group. However, person-centered approaches are 
more interested in an individual who experiences symptoms. The subgroups can be 
categorized into an “all high symptom” subgroup and a “high physical symptoms and low 
psychological symptoms” subgroup. Thus, employing person-centered approaches could 
help to determine subgroup membership based on patients’ symptoms and the 
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examination of the relationships between the subgroups and health outcomes 
(Miaskowski et al., 2006).  
Variable-centered approaches describe associations among variables and require 
an assumption be met that the population is homogeneous regarding the relationships 
between variables (Laursen & Hoff, 2006). Person-centered approaches describe 
similarities and differences among individuals while considering how variables relate to 
each other (Laursen & Hoff, 2006), and assume that the target population is 
heterogeneous. In prior research, clusters based on reported symptoms have been 
identified using variable-centered approaches but not based on the individuals who 
experienced these symptoms using a person-centered approach (Dodd, Cho, Cooper, & 
Miaskowski, 2010; Masyn, 2013). Some researchers might consider these approaches 
opposite, but these approaches are complementary (Masyn, 2013). More recently, person-
centered approaches, which employ some form of mixture modeling or cluster analysis, 
have shown great utility in the study of symptom clusters (Dodd et al., 2010; 
Miaskowski, Aouizerat, Dodd, & Cooper, 2007; Miaskowski et al., 2015). The person-
centered approaches allow for the identification of subgroups of patients based on their 
levels of symptoms. A subgroup can be identified that is at high risk for a more severe 
symptom experience (Miaskowski et al., 2007).  
Studying the impact of late effects on health behaviors beyond HRQOL using a 
person-centered approach is an important area for study. It could allow for better 
understanding of unique symptoms of childhood cancer survivors, so that targeted 
interventions can be developed for this group.  
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Purpose and Specific Aims 
This study is a secondary data analysis using the SJLIFE data. The broad goal of 
this research is to investigate the impact of late effects on health outcomes (i.e., HRQOL) 
in survivors of childhood cancer. This project investigates the association between 
subgroup memberships based on effect of late effects on HRQOL using cluster mixture 
modeling.  
 The Specific Aspects of Aims are:  
Aim A: to identify homogenous subgroups of survivors who share common profiles 
across multiple symptom classes including pain, cardiac and pulmonary symptoms, 
disfigurement, learning/ memory problems, and psychological symptoms (i.e., anxiety, 
depression, somatization, and global distress).  
Aim B: to examine demographic and clinical factors as predictive of subgroup 
memberships.  
Aim C: to find association between subgroup memberships and HRQOL.  
Aim D: to examine the main effects of predictors on HRQOL while considering 
subgroup membership.  
Hypotheses of Aims  
Aim A. Several meaningful subgroups of survivors with heterogeneous symptom patterns 
will be identified (e.g., class 1: high psychological symptoms and high physical-related 
symptoms; class 2: low psychological symptoms and high physical symptoms; class 3: 
high psychological symptoms and low physical symptoms; and class 4: low 
psychological symptoms and low physical symptoms).  
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Aim B. Demographic or clinical factors will differentially predict subgroup membership. 
For instance, survivors who experienced amputation due to bone tumor might fall into a 
subgroup whose members report high physical symptoms and high psychological 
symptoms (class 1).   
Aim C. Survivor membership in the subgroup high physical symptoms and higher 
psychological symptoms (class 1) will be associated with poorer physical aspects of 
HRQOL.  
Aim D. Subgroup membership has a moderating effect on the relationship between 
sociodemographic or clinical factors and HRQOL. For example, survivors who belong to 
the high physical and psychological symptom group (class 1) will have lower income and 
poorer physical and mental HRQOL.  
Dynamic Symptoms Model 
 A symptom is defined as a subjective experience about changes in body 
functioning, sensation, or cognition (Harver & Mahler, 1990). Symptom clusters are 
defined as two or more related symptoms occurring concurrently (Barsevick et al., 2006b; 
Kim et al., 2012). Survivors of childhood cancer are at risk of experiencing various 
symptoms (i.e., late effects) from their cancer treatment, and these symptoms could affect 
their health outcomes. With a focus on how to explain levels or clusters of symptoms 
with regard to health outcomes, the revised Dynamic Symptoms Model (Brant, Dudley, 
Beck, & Miaskowski, 2016) was chosen as a theoretical framework to guide this study. 
This model is revised from the symptom management model by the same authors (Brant, 
Beck, & Miaskowski, 2010). The Dynamic Symptoms Model consists of antecedents 
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(e.g., age, medical conditions), consequences (e.g., quality of life, functioning), symptom 
experience over time (e.g., temporality, intensity, quality, and distress), and interventions 
(see Figure 1). Compared to the original model, the Dynamic Symptoms Model is 
parsimonious and comprehensively demonstrates the relationships among antecedents, 
symptoms, and consequences of health outcomes.   
Several models have been used to explain the relationship between antecedents, 
symptoms and consequences. Compared to similar models such as the unpleasant 
symptoms model (Lenz, Suppe, Gift, Pugh, & Miligan, 1995) and symptom experience 
model (Armstrong, 2003), the Dynamic Symptoms Model provides a strong foundation 
for this project because it centers on antecedents of symptoms and articulates 
direct/indirect relationships between antecedents and consequences of symptoms. Parts of 
this theory are employed in this project. For example, a demographic factor (e.g., age, 
race, and gender) and a physiologic factor (e.g., medical condition, and types of 
treatment) under four categories of antecedents were used. Late effects (e.g., chronic 
conditions) were used as symptom experiences. The distress and temporality under 
symptom experience were also used. With regard to consequences, quality of life was 
used as the only outcome variable. In this model, intervention and symptom management 
strategies were not used. Using the Dynamic Symptoms Model, subgroups of survivors of 
childhood cancer who have symptom clusters were identified (aim A), demographic and 
clinical factors as antecedents of subgroup membership were examined (aim B), HRQOL 
differences between subgroup membership were examined (aim C), and the moderating 
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effects of subgroup memberships between demographic and clinical factors and HRQOL 
were examined (aim D).  
 
Figure 1  
 
Dynamic Symptoms Model 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Used by permission from the committee member (Dr. Dudley)  
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Literature Related to Dynamic Symptoms Model  
Since the Dynamic Symptoms Model was released in 2016, there have been no 
reported studies that employed this theory. Therefore similar theories were reviewed that 
included the concepts of “antecedents” and “symptom clusters” and that examined how 
the Dynamic Symptoms Model was developed. Kim and colleagues used the Unpleasant 
Symptoms Model (Lenz et al., 1995) to predict the intensity of cluster symptoms in 
survivors of breast cancer using a longitudinal design (Kim, Barsevick, & Tulman, 2009). 
This theory indicates that multiple symptoms can occur at the same time and that various 
factors (e.g., situational, physiologic, and psychologic) affect symptoms. As a result, 
those authors identified two groups of predictors of symptom intensity: a 
psychoneurological symptom cluster and an upper gastrointestinal symptom cluster. 
Across time, age and treatment modality were consistently significant predictors of the 
upper gastrointestinal symptom cluster, and baseline physical performance status was a 
consistent significant predictor of the psychoneurological symptom cluster. For example, 
young women and women undergoing chemotherapy experienced more intense 
gastrointestinal symptoms. Patients with better physical performance status reported 
symptoms of low intensity. Thus, Kim and colleagues (2009) addressed the importance of 
assessing baseline physical performance status to decrease upper gastrointestinal 
symptom clusters in patients with cancer.  
Outcomes that are considered within the unpleasant symptoms model include 
function, cognition, and physical performance. The theory is parsimonious and focuses 
primarily on symptoms and outcomes. However, categories under antecedents and 
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outcomes of this theory are not well defined (Brant et al., 2010). For example, the 
situational factors are not defined and performance is the only outcome using this theory. 
In addition, this theory can describe the relationship between symptoms and outcomes, 
but it does not address factors that can intervene to decrease patients’ symptoms (Brant et 
al., 2010). The Kim et al. (2009) study showed the relationship between predictors of 
each symptom cluster; this finding might be helpful in determining which patient is 
vulnerable to experience a certain symptom cluster. However, as Brant et al. (2010) 
mentioned, since the definition of each antecedent is not well defined, this theory is not 
appropriate to use as the current study’s framework.  
The symptom experience model (Armstrong, 2003) is a complex design and 
includes detailed factors compared to the unpleasant symptom model. Brant and 
colleagues used the symptom experience model to explain the antecedents of symptoms 
and to examine the trajectories of symptoms including fatigue, pain, depression, distress, 
and sleep disturbance across time (Brant et al., 2011a). Although the symptom experience 
model does not include trajectories of symptoms, Brant and colleagues used this model to 
explain antecedents and symptom characteristics (e.g., frequency, intense, distress, and 
meaning). In addition, this model does not provide for the direct relationship between 
antecedents and consequences. After the completion of her study, Brant created a 
modified version of the symptom experience model that includes time trajectories for 
symptoms (Brant et al., 2010).  
In her next study, Brant and her team used the modified version of the symptom 
experience model. That study’s purpose was to examine the trajectories of six common 
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symptoms during chemotherapy across time (Brant et al., 2011b). Brant and colleagues 
considered symptoms as changing over time due to interaction with antecedents such as 
age, gender, or types of treatment. Employing the modified model, they sought to explain 
the trajectories of symptom clusters over time. Understanding a higher risk group of 
symptom clusters aids in the development of risk assessment tools and tailored 
interventions for patients undergoing cancer treatment (Brant et al., 2011b). Based on the 
modified model, Brant and colleagues created the Dynamic Symptoms Model in 2016 
(Brant et al., 2016). The Dynamic Symptoms Model was used to guide the current study; 
it includes detailed explanations about each antecedent, and direct and indirect 
relationships between antecedents and consequences. In addition, this model reflects the 
characteristics of symptoms including a symptom experience factor (e.g., temporality and 
distress) and a symptom trajectory factor, along with consequences of the symptoms, 
such as quality of life.  
Significance of the Study  
This study includes several meaningful aspects that have the potential to improve 
HRQOL in survivors of childhood cancer. First, this study may fill gaps in symptom 
cluster identification and further elucidate their impact on HRQOL in survivors of 
childhood cancer. Several studies have identified subgroup membership of symptoms 
among adults with cancer, including breast, colon, prostate, or mixed disease groups of 
patients; however, there are few studies of survivors of childhood cancer. In addition, this 
study will test a recently developed theory, the dynamic symptoms model, to examine the 
relationships between demographics, symptom clusters, and quality of life. Using this 
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theory could help to identify antecedents that promote better HRQOL. Third, this study 
could provide critical information to the healthcare community that will enable providers 
to tailor individual survivorship plans for survivors of childhood cancer. HRQOL has 
multidimensional aspects; identifying symptom clusters associated with better HRQOL 
may be helpful for designing interventions for vulnerable groups that have severe and 
multiple symptoms. For example, if pain and fatigue are considered one cluster, targeting 
decreasing pain may attenuate fatigue as well. Another potential benefit of this study is 
that the identification of symptom clusters and their effects on HRQOL could be cost-
effective for patients and clinicians. It may be possible to detect symptoms early and 
expect symptoms in advance, allowing for opportunities to reduce related symptoms.  
  
20 
 
CHAPTER II 
REVIEW OF THE LITERATURE 
 
The focus of the current study is to better understand symptoms and symptom 
clusters among survivors of childhood cancers, and the effect of the symptom clusters on 
survivors’ HRQOL. This chapter examines the literature associated with several factors 
that are known to affect health-related quality of life (HRQOL) of those with childhood 
cancer. Assessment of HRQOL in survivors of childhood cancer is important in order to 
make meaningful survivorship plans. To obtain accurate information about HRQOL 
based on the survivors’ developmental period, the literature was searched separately for 
adolescents and for children with cancer. Many studies include adolescents as childhood 
cancer survivors (including those 0 to 18 years old at time of cancer diagnosis). However, 
combining participants across this broad age range may mask the impact of unique 
developmental issues that may arise during a cancer diagnosis at vulnerable ages, 
especially during adolescence. Thus, the literature was searched separately for survivors 
of adolescent and childhood cancer. Large national studies were also included in order to 
compare findings with studies that reported relatively small sample sizes.  
Late Effects after Cancer Treatment during Childhood and Adolescence  
Cancer diagnosis and treatment during childhood and adolescence might result in 
various late effects. Most children diagnosed with solid tumors are treated with platinum 
drugs (cisplatin/carboplatin), and/or vinca-alkaloid (vincristine or vinblastine) drugs. 
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These solid tumors include osteosarcoma, Ewing’s sarcoma, rhabdomyosarcoma, and 
Wilms’ tumor. Platinum drugs have complications including acute neuropathy within a 
short time after cancer treatment (Cavaletti, Alberti, Frigeni, Piatti, & Susani, 2011; 
Windebank & Grisold, 2008). Also, these drugs have long-term effects that are associated 
with increased risk of sensory and mobility impairments (Ness et al., 2013). Use of vinca-
alkaloid drugs is related to peripheral neuropathy that occurs within several months after 
cancer treatment. The vinca-alkaloid drugs, often prescribed for a few years to those with 
acute lymphoblastic leukemia, can cause long-term effects such as mild neuropathy 
(Lehtinen et al., 2002; Ness et al., 2012; Ramchandren et al., 2009). The long-term effect 
of neuropathy has been found to be associated with an increased risk of motor 
impairment (Ness et al., 2013).  
Anthracyclines are used in the treatment of various types of childhood cancers. 
Late cardiotoxicity can occur one year or more after completion of cancer treatment. This 
cardiotoxicity can include cardiac function abnormalities, dilated cardiomyopathy, and/or 
heart failure. The risk factors for cardiomyopathy were associated with accumulative 
doses of anthracyclines and included mediastinal irradiation, young age at exposure, 
female sex, and time passed after the treatment (Blanco et al., 2011; Mulrooney et al., 
2009). Thirty years after treatment, survivors who were treated with a cumulative 
anthracycline dose ≥ 250 mg/m2 had a cumulative incidence of congestive heart failure 
exceeding 7.5% (Mulrooney et al., 2009).  
During the 1960s and 1970s, whole-brain radiotherapy was used for childhood 
leukemia cancer patients to decrease central nervous system cancer relapse. At present, 
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whole-brain radiotherapy is used only for patients with leukemia who are at high risk of 
CNS relapse (Pui & Howard, 2008). Survivors of childhood cancer who were treated 
with ovarian/uterine radiation and received high accumulating doses of alkylating agents 
or cyclophosphamide (2-3 g/m2) are at high risk of premature menopause and less likely 
to become pregnant (Green et al., 2009, 2010; Sklar et al., 2006). Also, leukemia and 
lymphoma survivors who were treated with brain radiotherapy (dose of ≥ 30 Gy) have 
been found to have an increased risk of stroke compared to their healthy siblings (Bowers 
et al., 2006). Based on treatment benefits and risks identified over time, radiation 
treatments dosages and frequencies have been changed for children with cancer. 
Findings from an analysis using the nationwide sample in the Childhood Cancer 
Survivor Study (CCSS) showed the prevalence of late effects and types of late effects 
experienced by childhood cancer survivors. Several researchers used CCSS data and 
identified various issues including late effects, health-related quality of life (HRQOL), 
health behaviors, mortality, and psychosocial effects (Hudson et al., 2003; Maunsell et 
al., 2006; Zebrack et al., 2002; Zeltzer et al., 2008). Based on the findings of these 
studies, it is clear that long-term survivors of cancer in childhood and adolescence have a 
high risk of chronic health conditions. For example, thirty years after cancer diagnosis, 
the expected rate of chronic health conditions was 73.4% (Oeffinger et al., 2006). In the 
same study, survivors had eight times increased relative risk of a serious chronic health 
condition compared to siblings who had not experienced cancer. Similarly, late effects 
commonly occur long after cancer diagnosis and treatment. According to a recent SJLIFE 
study, more than 90% of long-term (between 10 to 40 years after cancer diagnosis) 
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survivors of pediatric cancer suffer from one or more symptoms including pain, cardiac 
and pulmonary symptoms, learning/memory problems, anxiety, depression, and/or 
somatization (Huang et al., 2013).  
Also, survivors who were treated for specific types of cancer have an increased 
risk for secondary cancer. Twenty years after cancer diagnosis during childhood, 20% of 
female survivors who were treated with chest radiotherapy were diagnosed with breast 
cancer (Bhatia, 2003). In addition, survivors who were treated with chest radiotherapy 
have a 20% increased risk of coronary artery disease two decades beyond the cancer 
diagnosis (Reinders et al., 1999). Also, a large cohort study in Britain among Hodgkin 
disease in childhood survivors found a risk of myocardial infection that was three times 
higher than in healthy populations (Swerdlow et al., 2007). Similarly, adult males who 
were treated for testicular cancer in childhood have an increased risk of cardiovascular 
complications such as hypertension, and they reported complications such as metabolic 
syndrome and obesity (Huddart et al., 2003; Nuver et al., 2005; van den Belt-Dusebout et 
al., 2007).  
Fortunately, the incidence of late effects can be decreased with prevention 
strategies such as engaging in healthy behaviors, and the early detection of late effects 
could decrease their long-term consequences (Tonorezos & Oeffinger, 2011). As 
previously mentioned, these late effects could occur singly (one symptom) but could also 
occur concurrently as several symptoms referred to as symptom clusters. A few 
researchers started examining the concept of symptom clusters to explain relationships 
between symptoms and health outcomes among adults with cancer (Barsevick et al., 
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2006a; Dodd, Dibble, et al., 2001b; Miaskowski et al., 2006). It is important to study 
symptoms clusters among childhood cancer survivors.  
Initially, Dodd and colleagues identified symptom clusters of pain, fatigue, and 
sleep and their effects on functional health status among cancer patients undergoing 
cancer treatment (Dodd et al., 2001a). Other researchers identified symptom clusters in 
adults with various types of cancer (Barsevick et al., 2004; Brant et al., 2011b; 
Miaskowski et al., 2015) as well as a single type of cancer, including lung, breast, and 
prostate (Beck, 2012; Dodd et al., 2010; Gold et al., 2016; Legler, Davis, Potosky, & 
Hoffman, 2004). Symptom clusters varied depending on the characteristics of the 
symptom clusters. For example, researchers identified a psycho-neurological cluster (i.e., 
cognitive disturbance, depressed mood, fatigue, insomnia, and pain) (Kim, McDermott, 
& Barsevick, 2014), symptom experiences cluster (i.e., fatigue, sleep disturbance, 
depression, and pain) (Miaskowski et al., 2006), and clusters based on anxiety and 
depression scores (i.e., resilient, subsyndromal, delayed, and peak) (Gold et al., 2016).  
To date, most studies on symptom clusters have been related to adults with 
cancer, but three studies examined symptom clusters in survivors of childhood cancer 
(Hockenberry, Hooke, McCarthy, & Gregurich, 2011; Mattsson, El-Khouri, Ljungman, & 
von Essen, 2009; Yeh et al., 2008). These three studies had relatively small samples (less 
than 150) of survivors of childhood cancer. The way symptom clustering was used varied 
among the studies: Mattsson et al. (2009) used psychosocial status clustering vitality, 
mental health, and anxiety and clustered into five groups (Mattsson et al., 2009). 
Hockenberry and colleagues (2011) used emotional and physical symptoms and clustered 
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symptoms into two groups including a group with fatigue and depression and a group 
with gastrointestinal (GI) symptoms and performance status. Yeh and colleagues 
identified five symptom clusters including symptoms related to sensory discomfort and 
body image; circulatory and respiratory system malfunction; fatigue, sleep disturbance, 
and depression; body image and eating difficulties; and gastrointestinal irritations and 
pain (Yeh et al., 2008).  
Each group of researchers found several predictors that were related to each 
symptom cluster including gender, age, and type of cancer. For example, female 
survivors were linked to symptom clusters with worse psychosocial functioning 
(Mattsson et al., 2009) and fewer reported high GI symptoms and pain than male 
survivors (Yeh et al., 2008). Survivors who were older (current age between 16-19 years 
old) were associated with worse psychosocial functioning than survivors who were 
younger (13-15 years old) (Mattsson et al., 2009). Adolescent cancer survivors were 
linked to clusters with less activity and more sleep disturbance compared to child cancer 
survivors (10-12 years old) (Hockenberry et al., 2011). The cognitive ability of 
adolescents compared to children allowed them to understand their disease and recognize 
side effects of cancer treatment, which might have resulted in fatigue and sleep 
disturbances (Hockenberry et al., 2011).  
Hockenberry et al.’s (2011) study included various types of childhood cancer. 
Survivors with a bone tumor were associated with a cluster including fatigue and 
depression, and survivors with solid tumors were linked to a cluster with GI symptoms 
(vomiting and nausea) and lower performance status (Hockenberry et al., 2011). Patients 
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with leukemia reported more distress from symptoms in clusters with fatigue, sleep 
disturbance, and depression than patients with solid tumors or lymphoma. These 
inconsistent results might have been related to individuals with different types of cancer 
and treatments. Patients who had solid tumors received repeated intensive chemotherapy 
in a short amount of time such as six months to one year, whereas leukemia and 
lymphoma patients typically had intensive chemotherapy for a longer period of up to two 
years. Thus, patients with solid tumors might have had cumulative chemotherapy effects 
and a propensity to gastrointestinal problems (Hockenberry et al., 2011). Also, the 
treatment of leukemia with drugs like corticosteroid medications could have affected 
survivors’ mood and sleep patterns.   
Two studies (Hockenberry et al., 2011; Mattsson et al., 2009) categorized 
symptoms as symptom clusters and examined predictors of symptom clusters, but Yeh et 
al. (2008) studied the impact of symptom clusters on physical functions. Among five 
clusters, only the cluster with GI symptoms and pain was associated with good functional 
status. It was unclear, however, how patients with pain reported good functional status. In 
the Yeh et al. (2008) study, parents answered questions about functional measurements 
for their children, so it might have affected results differently than if the child had been 
the respondent (Yeh et al., 2008). Also, although the measurement was considered a 
reliable measure of functional status (Yeh & Hung, 2003), it only included a single item 
(Yeh et al., 2008). In future studies, where possible, standardized measurements and 
instruments of functional status or HRQOL need to be obtained directly from adolescents 
or children. These three studies (Hockenberry et al., 2011; Mattsson et al., 2009; Yeh et 
  
27 
 
al., 2008) did not have a large enough sample size to generalize findings and the studies 
did not examine the relationship between symptoms clusters and HRQOL in survivors of 
childhood cancer. The current study examined the effect of both physical and 
psychological symptom clusters on HRQOL among survivors of childhood cancer.  
The purpose of the current study that aimed to identify predictors of HRQOL is in 
line with the national cancer institute (NCI)’s research guidelines for cancer patients and 
the U.S. national guidelines to promote health and prevent diseases for Americans (i.e., 
healthy people 2020), and revealed predictors that could be used to prevent or maintain 
quality of life among survivors. Thus, before starting this current study, HRQOL-related 
literature was reviewed in order to better understand HRQOL. The aims for the literature 
review included (1) identify HRQOL status of survivors of childhood cancer; (2) identify 
factors that impact HRQOL among demographic or clinical variables; (3) examine other 
factors besides demographic or clinical variables thought to be significant predicators of 
HRQOL; and (4) identify appropriate HRQOL measurements for survivors of childhood 
cancer. This literature review focused on survivors of childhood cancer.  
Health-Related Quality of Life  
In 1948 the WHO defined health: “a state of complete physical, mental, and social 
well-being and not merely the absence of disease of infirmity” (WHO, 1948, p.1). In 
order to measure outcomes of health, health-related quality of life or quality of life has 
been used. As previously mentioned, the concepts of HRQOL and QOL have been used 
interchangeably in the literature. However, several researchers have made some 
distinctions. According to previous studies, quality of life has several key concepts. 
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Individuals have their own perspectives on QOL which depends on past and present 
experience and expected hope for the future. In a medical context, QOL is considered to 
have multidimensional aspects that combine to describe several functions (Aaronson et 
al., 1991). Also, QOL can include both subjective and objective health status in several 
domains (Testa & Simonson, 1996). Aaronson and Beckman (1987) defined QOL 
domains as consisting of four aspects: (a) functional status (e.g., self-care, mobility, 
physical activities, role activities), (b) disease-related and treatment-related physical 
symptoms (e.g., pain, nausea), (c) psychological functioning (e.g., anxiety, depression), 
and (d) social functioning.  
HRQOL refers to focus on the impact of health and illness and is distinguished 
from the broader concept of overall well-being (Eiser, 2007). HRQOL is defined as a 
multidimensional construct that comprises several domains including physical, social, 
emotional, and cognitive functioning (Spieth & Harris, 1996). For this current study, 
HRQOL instead of QOL is used because of its focus on health-related well-being 
including multidimensional aspects of quality of life. Some researchers have developed 
HRQOL content and measurements based on this WHO definition while considering 
multidimensional aspects (Eiser & Morse, 2001; Varni, Seid, & Kurtin, 2001). In 
addition, the WHO supports a theory of QOL; “the individuals’ perceptions in the context 
of their culture and value systems, in relation to their personal goals, standards, and 
concerns” (WHOQOL Group, 1994)(p. 24).   
Historically, HRQOL research has been mostly limited to adult studies (Huebner, 
1991; Veenhoven & den Buitelaar, 1993). However, in the 1990s, researchers began 
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studying children and adolescents’ HRQOL (Gilman & Handwerk, 2001). Unlike adult 
cancer patients, children and adolescent cancer patients need detailed survivorship plans 
due to the unique developmental needs of their age. Also, after completion of cancer 
treatment, several complications can occur in these populations that do not apply to adults 
who have cancer. Clinicians must recognize that children and adolescents with cancer 
may have different views on life than adults, and thus it is important to understand what 
QOL means directly from children and adolescents’ perspective (Eiser, 2007; Fayed, 
Schiariti, Bostan, Cieza, & Klassen, 2011).  
Most of the literature reports that survivors of childhood and adolescent cancer 
have had similar or better QOL statuses compared to healthy control groups. However, a 
subgroup of survivors reported significant psychological distress and poor QOL 
(Maunsell et al., 2006; Zeltzer et al., 2008). Several factors are known to affect lower 
QOL. These include late effects, low income, gender, and type of cancer among survivors 
of childhood cancer. Late effects include physical symptoms, fatigue and psychological 
distress (Maunsell et al., 2006; Meeske et al., 2007; Zebrack et al., 2008). However, there 
is lack of study to examine the relationship between kinds of treatment variables and 
quality of life among long-term survivors of childhood cancer. Thus, identifying clinical 
factors related to HRQOL among this population is important to aid clinicians in their 
decision making and to help survivors understand their survivorship care plans. Further, 
this could help in the engagement of survivors in following their survivorship plans that 
will help them to achieve their optimum level of health across their lifespan.  
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Using appropriate HRQOL measurements for childhood cancer is essential to 
accurately measure QOL and to understand survivors’ unique needs. HRQOL lacks a 
standard definition and various HRQOL measurements have been used for children and 
adolescents with cancer without considering their unique needs such as developmental 
tasks. For example, when children are become adolescents, they need to become 
independent. Thus, these studies revealed that the act of assessing HRQOL and providing 
opportunities for the patient to discuss their HRQOL can result in improvement of 
communication between patients and healthcare providers and increase patient 
satisfaction, and information gleaned about the patient’s HRQOL can provide. Further, 
this information can aid providers in detecting complications early and it could also help 
clinicians in their clinical decision making regarding the patient’s plan of care (Eiser, 
2007; Varni, Burwinkle, & Lane, 2005). Thus, HRQOL concepts should be considered in 
the design of long-term survivorship care plans for survivors of childhood cancer. 
HRQOL among Survivors of Childhood Cancer  
HRQOL status as well as HRQOL-related factors among survivors of childhood 
cancer are described below.  
HRQOL Status.   
Overall, the majority of survivors of childhood cancer reported physical and 
psychological HRQOL scores similar to healthy control groups  (Castellano-Tejedor et 
al., 2015; Chan et al., 2014; Larsson et al., 2010; Mannix, Feldman, & Moody, 2009; 
Mattsson, Ringner, Ljungman, & von Essen, 2007; Mort, Salantera, Matomaki, Salmi, & 
Lahteenmaki, 2011; Ruccione, Lu, & Meeske, 2013).  
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However, nearly 20% of the survivors of childhood cancer reported lower psychosocial 
scores, a higher anxiety level, or having emotional distress than a healthy control group 
(Ander et al., 2016; Ruccione et al., 2013).  
 Risk Factors.  
Risk factors for poor HRQOL among survivors of childhood cancer include type 
of cancer, type of treatment, chronic illness, late effects (e.g., symptoms), and patient 
demographics, including age and gender. For example, survivors of childhood central 
nervous system (CNS) tumors reported poorer psychological functioning than leukemia 
survivors (Meeske et al., 2007; Ruccione et al., 2013) and this was found to be negatively 
associated with the physical functioning of HRQOL (Chan et al., 2014). On the contrary, 
cancer diagnosis with leukemia was related to protective factors for better HRQOL. 
Leukemia survivors reported better overall QOL than survivors of other types of 
childhood cancer (O’Leary, Diller, & Recklitis, 2007), and better physical functioning 
than those with osteosarcoma (Mört et al., 2011). Leukemia or lymphoma, that were 
known to have higher survival rates compared to other types of cancer (Howlader et al., 
2014), could be related to better HRQOL. Thus, survivors who have CNS tumors are 
considered more at risk for diminished HRQOL compared to survivors who have 
leukemia and lymphoma. 
 Late effects. Potential complications from cancer treatment or late effects have 
been associated with poor physical functioning including obesity, vision impairment and 
hearing problems, symptoms (such as pain and nausea), and impaired neurocognitive 
functioning among survivors of childhood cancer (Arslan, Basbakkal, & Kantar, 2013; 
  
32 
 
Hocking, Hobbie, Deatrick, Hardie, & Barakat, 2015; Huang et al., 2013; Kazak et al., 
2010; Mannix et al., 2009; Maunsell et al., 2006; Maurice-Stam et al., 2009; Rhee et al., 
2014). In addition, several factors including fatigue, generalized pain, depression, 
posttraumatic distress, and sleep disturbance have been found to be related to lower 
psychological functioning among childhood cancer survivors (Gordijn et al., 2013; 
Meeske et al., 2007; Ruccione et al., 2013; Rueegg et al., 2013). A recent study examined 
HRQOL among survivors of adolescent cancer (who were diagnosed from ages 10 to 18 
years) using CCSS data, and survivors who experienced disfigurement (e.g., scarring of 
head or neck) had two times the relative risk of poor HRQOL compared to survivors 
without disfigurement (Nolan et al., 2014).  
 Treatment intensity. There are inconsistent findings about the effect of treatment 
intensity on HRQOL. Treatment intensity indicates level of treatment from least to most 
intensive and includes treatment modalities based on types and stages of cancer (Werba 
et al., 2007). Higher treatment intensity has been negatively associated with poorer 
physical functioning aspect of HRQOL for survivors of child and adolescent cancer for 
those diagnosed between 10 to 21 years old (Bitsko, Stern, Dillon, Russell, & Laver, 
2008; Nolan et al., 2014). Survivors of adolescent cancer who were treated with certain 
types of chemotherapy (i.e. alkylating agents) or radiation to the pelvis had 1.5 times 
relative risk of poor HRQOL (Nolan et al., 2014). Further, the intensity of treatment 
could impact patients’ HRQOL and the burden on the patients’ families (Kazak et al., 
2010). In particular, survivors of childhood cancer who experienced one or more 
treatment modalities (e.g., radiation, chemotherapy and bone-marrow transplantation) or 
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experienced radiation therapy or bone marrow transplantation reported worse HRQOL 
than those treated with surgery only (Kazak et al., 2010). This finding is similar to 
nationwide studies using CCSS data on long-term survivors of childhood cancer and the 
participants. These survivors were nearly 20 years beyond their cancer diagnoses 
(Maunsell et al., 2006; Rueegg et al., 2013; Zeltzer et al., 2008). However, in another 
study, treatment intensity was not negatively associated with HRQOL among survivors of 
childhood cancer (Barakat, Marmer, & Schwartz, 2010; Ruccione et al., 2013). The 
Barakat et al. and Ruccione et al.’s studies included participants with a shorter-term 
survivorship period (i.e., 6 months to 20 months after cancer diagnosis), which is a 
shorter period than that of long-term survivors in the Barakat et al. and Ruccione et al. 
studies (Maunsell et al., 2006; Zeltzer et al., 2008).  
 According to the definition of late effects by the NCI, the complications of 
treatments could occur immediately or several years after a cancer diagnosis (NCI, 2016). 
Since studies on HRQOL in survivors of childhood cancer have used different HRQOL 
measurements, it is difficult to directly compare these studies’ findings (Barakat et al., 
2010; Maunsell et al., 2006; Rueegg et al., 2013). Treatment intensity ratings are 
objective measures, whereas HRQOL ratings are subjective measures and are influenced 
by multiple factors including emotions, perceptions about the cancer experience, and 
social support from family or friends (Ruccione et al., 2013).  
 Gender. Female survivors of adolescent cancer have reported poorer overall 
HRQOL (Ander et al., 2016; Canning, Bunton, & Talbot Robinson, 2014; Mattsson et al., 
2009; Nolan et al., 2014). In particular, in Nolan and colleagues’ study, female survivors 
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had two times relative risk of poorer HRQOL than male survivors. This gender factor is 
in line with three other studies using the CCSS data that included a nationwide sample of 
survivors of childhood cancer that received their cancer diagnosis less than 19 years old 
from CCSS (Maunsell et al., 2006; Zeltzer et al., 2008) and a nationwide sample in Hong 
Kong (Chan et al., 2014). Female survivors of adolescent cancer (who were diagnosed 
with cancer between 13 to 19 years old) were found to have higher anxiety levels than 
male survivors of adolescent cancer immediately after the cancer diagnosis. These 
anxiety levels decreased to a normal range within four years after the cancer diagnosis 
(Ander et al., 2016).  
In addition, female survivors of childhood cancer are found to have higher 
psychological HRQOL than healthy siblings (Rueegg et al., 2013). However, gender 
difference on HRQOL has also been demonstrated in healthy populations. In one study, 
Mört and colleagues compared HRQOL status between survivors of childhood cancer 
and a healthy control group. The healthy females in the healthy control group reported 
lower HRQOL than males (Mört et al., 2011). On the contrary, in another study, gender 
and age were not associated with HRQOL. The participants were in the early 
survivorship period (20 months since cancer diagnosis) (Barakat et al., 2010). However, 
the previously mentioned studies included long-term survivors with an average of 15 
years since their cancer diagnosis (Maunsell et al., 2006; Mört et al., 2011; Zeltzer et al., 
2008). Thus, according to findings from the examination of large datasets, being a female 
survivor has a negative effect on HRQOL, short-term and long-term after cancer 
diagnosis.  
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Demographic factors in addition to gender. Demographic factors beyond gender 
have been found to be associated with HRQOL. Several demographic factors were 
negatively associated with HRQOL in survivors of adolescent cancer including 
unemployment status, living alone, and low household income (< $20,000) (Nolan et al., 
2014). This finding is likely secondary to employment being such an important part of a 
young adult’s life in order to provide financial support, development of a social life, and 
in order to identify roles in society (Blanc, 2004; Wanberg, 2012).  
 Protective Factors.  
Factors related to better HRQOL in survivors of childhood cancer include time 
passed since cancer diagnosis, age, education level, subjective feelings such as optimism, 
happiness and self-concept, social support, and family functioning (Mannix et al., 2009; 
Ruccione et al., 2013; Spangler, 2009).   
Time elapsed. Survivors of adolescent cancer (who were diagnosed with cancer 
between 13-19 years of age) have reported that their QOL improved with time following 
their cancer diagnosis (Ander et al., 2016; Jörngården, Mattsson, & von Essen, 2007; 
Larsson et al., 2010). For example, from six months to two years after cancer diagnosis, 
survivors demonstrated similar HRQOL to a healthy control group (Arpawong et al., 
2013; Jörngården et al., 2007; Ruccione et al., 2013). However, 20% of the survivors had 
lower psychosocial functioning than the mean of the ‘pediatric quality of life 
psychosocial functioning’ measurement (Ruccione et al., 2013). On the contrary, in one 
study, survivors’ HRQOL was lower when compared to a healthy control group in the 
same time period (Cantrell & Lupinacci, 2008). However, the Cantrell and colleagues 
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research had a comparatively smaller sample size (n = 35) than the other three studies 
that included more than 50 participants (Jörngården et al., 2007) and nearly 100 
participants (Arpawong et al., 2013 & Ruccione et al., 2013). Generally, the studies with 
larger sample sizes reported that survivors’ HRQOL was comparable to healthy control 
groups.  
Interestingly, four years after cancer diagnosis, survivors reported higher HRQOL 
than a healthy control group (Ander et al., 2016; Larsson et al., 2010). Similarly, using a 
longitudinal design comparing survivors of adolescent cancer from six months to ten 
years after their cancer diagnosis with a healthy control group, the mental summary 
scores of HRQOL showed no change in this period, but the physical summary score of 
HRQOL improved over time (Ander et al., 2016). Overall, survivors of adolescent with 
cancer reported comparable or better physical or psychosocial HRQOL than the healthy 
control group. In order to confirm these findings, more research is necessary for survivors 
of childhood cancer between four to ten years after cancer diagnosis.  
 Age. The age of the adolescent (15-17 years old) has been shown to positively 
affect psychosocial HRQOL when compared to younger adolescents (younger than 15 
years old) among survivors of childhood cancer (Ruccione et al., 2013). However, adult 
survivors of adolescent cancer (current age 35 and older) reported poorer physical 
HRQOL compared to younger survivors (current age 25 to 34 years old) (Nolan et al., 
2014). This finding might be related to time passed since cancer diagnosis and occurrence 
of late effects. Ruccione et al.’s study only includes survivors within six months of 
completion of cancer treatment and Nolan et al.’s study includes survivors more than ten 
  
37 
 
years after treatment completion. Also, for survivors who early in their survivorship, late 
effects might not yet have occurred. Long-term effects of cancer treatment could occur 
decades after cancer diagnosis.  
Education. Higher education level is also related to better HRQOL among 
survivors of childhood cancer. Survivors who had more than a high school education had 
better physical and psychological summary scores than survivors with less than a high 
school education in studies with larger sample sizes such as the CCSS or St. Jude 
Children’s Research Hospital study (Huang et al., 2013; Nolan et al., 2014; Zebrack et 
al., 2002). Higher education might be related to using coping strategies that change 
negative thoughts about the past cancer experience to more positive thoughts. They might 
have learned these skills during their education.  
Subjective feelings. Higher scores of a happiness measure have been associated 
with better QOL and fewer depressive symptoms, regardless of cancer treatment, in 
survivors of childhood cancer (Bitsko et al., 2008; Kazak et al., 2010). Also, some 
survivors of adolescent cancer (those who were diagnosed with cancer between 13-21 
years old) have reported high optimism scores, which was associated with fewer physical 
symptoms (Mannix et al., 2009). Mannix and colleagues suggested that optimism may 
play a protective role by preventing painful thoughts and by supporting survivors to cope 
with their illness.  
Perceived social support. Perceived social support from parents and clinicians 
predicted better psychosocial functioning among survivors of adolescent cancer (those 
who were diagnosed with cancer between 11 to 21 years old), but did not predict physical 
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QOL (Spangler, 2009). In particular, treatment-related variables including CNS radiation 
or bone marrow transplantation have been found to negatively affect physical QOL about 
three times as much as perceived social support. However, after controlling for the effects 
of CNS tumor diagnosis and treatment with CNS radiation, perceived social support from 
parents and psychiatrists did significantly predict better psychosocial HRQOL (Spangler, 
2009). This finding indicated the importance of social support from family members and 
care providers after completion of cancer. Similarly, better family functioning scores and 
higher parental overprotection scores predicted better psychosocial QOL in survivors of 
childhood cancer (Barakat et al., 2010). Social support from parents and good 
communication between parents and their children during cancer treatment has been 
shown to help these children have better HRQOL (Yeh, 2002). Also, social support from 
close friends has had mediating effects on the physical functioning aspect of HRQOL 
(Spangler, 2009). This is due to fact that peer relationships become more important in 
adolescence. Adolescents spend more time with peers and value peers’ opinions (Brown 
& Larson, 2009).  
Ethnicity. There have been a few research studies examining the impact of 
ethnicity on HRQOL among survivors of childhood and adolescent cancer. However, 
with such few studies, it is unclear whether ethnicity plays a role in HRQOL, but studies 
do reveal some relationships (Arpawong et al., 2013; Mannix et al., 2009; Zeltzer et al., 
2008). Better HRQOL has been reported among non-Hispanic White survivors of 
adolescent cancer (Arpawong et al., 2013; Mannix et al., 2009). Similarly, in 7,147 
survivors of childhood cancer using the CCSS data, Hispanic cancer survivors reported 
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more somatization and overall distress scores (i.e., sum of somatization, symptoms of 
depression, symptoms of anxiety), and they reported poorer scores on the physical and 
social functioning subscales of HRQOL than non-Hispanic White cancer survivors 
(Zeltzer et al., 2008). Nolan and colleagues (2014) examined predictors on HRQOL using 
only survivors of adolescent cancer using the CCSS data (Nolan et al., 2014). They found 
that Hispanic or other races’ cancer survivors (not non-Hispanic Black) have higher risk 
of poor HRQOL than non-Hispanic White cancer survivors (1.03 and 2.51 respectively). 
However, in two other studies, Hispanic survivors of adolescent cancer (Mannix et al., 
2009) and childhood cancer (Ruccione et al., 2013) reported similar HRQOL to the norm, 
and they positively rated their overall health (Meeske et al., 2007). These two studies 
have small sample sizes, less than 100, as compared to the CCSS nationwide sample. 
Overall, Hispanic survivors of adolescent cancer reported comparable psychosocial 
functioning scores with the norm, but long-term Hispanic survivors of childhood cancer 
reported poorer psychosocial functioning and a higher distress level. Post-traumatic 
growth might explain why some survivors reported good psychological functioning. The 
cancer experience might be the traumatic event and higher psychosocial functioning 
could be related to posttraumatic growth (Zeltzer et al., 2008). 
Post-traumatic growth occurs when individuals find meaning in traumatic events. 
As a result, these individuals have higher levels of functioning than which existed prior to 
the event (Linley & Joseph, 2004; Widows, Jacobsen, Booth-Jones, & Fields, 2005). 
Non-Hispanic White childhood cancer survivors reported greater post-traumatic growth 
(PTG) than Hispanic childhood cancer survivors that was positively related to 
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psychosocial functioning though negatively related to physical functioning (Arpawong et 
al., 2013).  Despite this finding, of the 94 participants, 18% (n = 17) reported lower 
psychosocial functioning than the norm (Arpawong et al., 2013), and school and 
emotional functioning was lower in Hispanics than in non-Hispanic cancer survivors 
(Meeske et al., 2007). This might be related to the fact that Hispanics in the U.S. are 
generally of lower socioeconomic status than non-Hispanic whites.  
Summary of Literature Review on HRQOL.  
In this literature review, the current HRQOL status and factors that impact 
HRQOL among survivors of childhood and adolescent cancer were provided. Overall, 
except for subgroups of patients, survivors’ QOL is comparable to healthy controls. 
However, the subgroup who experiences lower HRQOL should not be ignored. Ignoring 
this lower HRQOL in subgroups may lead to an aggravation of their HRQOL or negative 
impacts on their health outcomes. It is also necessary to think about whether standard 
HRQOL measurements are appropriate for survivors who are young adults or 
adolescents. Some researchers have questioned whether a survivor’s good HRQOL score 
was related to measurement issues or to response bias. Thus, these researchers used 
interviews to verify the HRQOL measurements (Nightingale et al., 2011; Quinn, Huang, 
Murphy, Zidonik-Eddelton, & Krull, 2013).  
In addition, O’Leary et al. (2007) measured self-deception enhancement (SDE) to 
examine whether survivors of childhood cancer were biased about their cancer-related 
experience (O’Leary et al., 2007). The SDE measures the possibility that high scoring 
individuals overestimated their positive attributes due to lack of insight or denial of 
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current problems. The survivors’ mean SDE score was higher (7.5) than the norm (5.8) 
for both genders, thus 40% of the survivors (43 of 107) were identified as biased 
respondents. It is important to review the HRQOL measurements used most often for 
survivors of childhood cancer in order to determine if these measurements are 
appropriate.  
 HRQOL Measurement.  
 
QOL assessment in pediatric oncology is an important piece of the cancer 
survivorship plan (Goodwin, Boggs, & Graham-Pole, 1994). This is because measures of 
QOL may generate clinical information that could help patients, their parents, and health 
professionals to make decisions about treatments or alternative therapies. Researchers 
used literature reviews to determine the best HRQOL measurements for their research 
purposes and participants’ ages. According to Fayed and colleagues’ review (2011), a 
most often used generic measurement of HRQOL is the Child Health Questionnaire, and 
three most often used measurements that are cancer-specific are the University of 
Minnesota Minneapolis-Manchester QOL Survey of Health, the PedsQL 3.0 cancer 
module, and the Pediatric Oncology Quality of Life Scale. Using a systematic review of 
survivors of childhood cancer, Anthony and colleagues report that the PedsQL-Cancer 
Module was the most commonly used cancer-specific instrument (Anthony et al., 2014). 
From these studies, there are no standard measurements for HRQOL in these populations. 
Thus, it is important to use a standardized measurement of QOL and to use more than one 
instrument in order to measure QOL comprehensively (Fayed et al., 2011). In addition, 
measurements should be chosen based on the research purpose (Anthony et al., 2014; 
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Eiser, 2007). Several researchers have suggested that in general, cancer-specific 
questionnaires are appropriate to use with cancer patients (Eiser, 2007; Fayed et al., 
2011). In addition, generic measures are useful if the research questions intend to make 
comparisons between cancer survivors and the average population (Eiser, 2007). Several 
researchers have suggested that QOL is not hypothesized to be measure one dimension, 
thus, even if a subdomain of QOL has low internal consistency, it may be needed to be 
included in order to measure overall QOL (Cella & Tulsky, 1990; Goodwin et al., 1994).  
Missing Content of Current HRQOL Measurements. Two studies found missing 
items in HRQOL measurement among young adult survivors of childhood cancer when 
surveying those between 17 and 37 years old (Nightingale et al., 2011; Quinn et al., 
2013). The missing items included perceived sense of self, romantic relationships, 
fertility/sexual functioning, and spirituality. These unique aspects of HRQOL are needed 
to comprehensively measure HRQOL among young adult survivors. Researchers can 
include such items to supplement questionnaires when studying HRQOL. In the current 
study, SF-36 was used to measure HRQOL without adding supplement questionnaires. 
Future research should test HRQOL measurements that include these items.  
 Lack of Survivorship Care.   
The earlier referenced Institute of Medicine (IOM) report suggests that all cancer 
survivors need to get follow-up care to monitor and prevent late effects and manage 
chronic conditions (Hewitt et al., 2003). In addition, cancer survivors are required to visit 
long-term follow-up (LTFU) clinics to detect late effects, provide information on health 
behaviors and access resources related to psychosocial, educational and socioeconomic 
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support (von der Weid & Wagner, 2003). The Children’s Oncology Group’s guideline for 
long-term follow-up care for survivors of childhood, adolescent, and young adult cancers 
emphasizes health care provider’s need to be aware of these late effects and health 
outcomes (Children’s Oncology Group, 2013).  
 However, according to a nationwide sample of 10,000 childhood cancer 
survivors using CCSS data, only 42% of survivors visited a hospital to get cancer-related 
medical treatment within the two years of the research period (Oeffinger & Hudson, 
2004), and long-term survivors rarely attended LTFU clinics (Arvidson, Söderhäll, 
Eksborg, Björk, & Kreuger, 2006; Nathan et al., 2008, 2009). Moreover, non-attenders of 
long-term clinics were not aware of the necessity to visit clinics (Ford, Chou, & Sklar, 
2013).  
According to studies about long-term follow-up among childhood cancer 
survivors in Switzerland, socioeconomic levels, demographic characteristics, and health 
beliefs including susceptibility, severity of late effects, and benefits to health behaviors 
affected survivor’s attendance rates at LTFU clinics. Also, perceived barriers were 
significantly associated with attendance at follow-up services (Michel et al., 2011). 
Younger survivors (less than 25 years old), single, and unemployed survivors with less 
than a high school education were more likely to attend LTFU clinics. Survivors who 
were diagnosed when older than 12 years and those who had more risks for complications 
after their treatments such as having a central nervous system tumor, those receiving 
radiotherapy, or those experiencing a cancer relapse, were more likely to attend LTFU 
(Michel et al., 2011).  
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There are also cultural differences among those attending LTFU. Racial/ethnic 
minority group members reported lower confidence in their ability to manage their 
survivorship care than did non-Hispanic White childhood cancer survivors. Minorities 
including African American and Hispanic childhood cancer survivors’ hospital visits rate 
was 1.5 times lower than non-Hispanic white childhood cancer survivors (Oeffinger & 
Hudson, 2004). The NCI suggests that cultural differences or socioeconomic factors 
could lead to health disparities. To decrease health disparities, NCI emphasizes that 
researchers must identify factors related to disparities in order to develop culturally 
appropriate approaches for cancer survivors (NCI, 2006). The SJLIFE study includes 
various ethnic groups including non-Hispanic whites, non-Hispanic blacks, and 
Hispanics. In the current study their HRQOL based on ethnic differences is revealed.   
Current Knowledge Gaps in HRQOL  
Among survivors of childhood cancer, protective factors for HRQOL include 
family functioning, time since cancer diagnosis, subjective feelings such as happiness, 
optimism, and self-concept, and social support. Risk factors include gender, type of 
cancer and treatment, and late effects. Identifying these factors could be helpful in 
detecting vulnerable individuals who might have poorer HRQOL. There is lack of 
survivorship plans that include regular assessment of HRQOL in young adult survivors of 
childhood cancer and lack of comprehensive HRQOL instruments that evaluate unique 
characteristics of this population. The most commonly used measurements are the SF-36 
and the Pediatric QL Generic Core Scale to assess multidimensional aspects of HRQOL, 
but these measurements are not sensitive to estimate developmental characteristics of 
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these populations. Additional items such as fertility/sexual function and romantic 
relationships might be added as supplemental questions to better understand HRQOL for 
these young adult survivors. Furthermore, it is necessary to choose measurements based 
on a study’s research purpose. 
More research is necessary on specific time periods after diagnosis among long-
term survivors of childhood cancer. As demonstrated in this literature review, time passed 
since diagnosis was positively associated with improved HRQOL. Most studies focused 
on the time frame up to four years after cancer diagnosis (Arpawong et al., 2013; 
Jörngården et al., 2007; Larsson et al., 2010), or on long-term survivors of childhood 
cancer more than 10 to 15 years after cancer diagnosis (Huang et al., 2013; Mört et al., 
2011; Spangler, 2009; Zeltzer et al., 2008). More research is necessary for those between 
four to ten years after cancer diagnosis in order to identify factors related to HRQOL 
status for this group. Also, among reviewed studies, most studies on HRQOL of survivors 
of childhood cancer used a cross-sectional design. There is a lack of study that has used a 
longitudinal design to know the individual change and longitudinal patterns of HRQOL 
after the completion of cancer treatment. Using a cross-sectional design cannot reveal the 
causal relationship between predictors and HRQOL. Thus, it is necessary to use a 
longitudinal design to find factors that are related to HRQOL across time.  
After completing cancer treatment, survivors of childhood cancer are required to 
regularly visit long-term follow-up clinics to detect late effects, promote disease 
understanding, and to be provided with information and resources, including health 
behavior, psychosocial, and educational support (von der Weid & Wagner, 2003). During 
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follow-up care, regular assessment of HRQOL is necessary to understand an individual’s 
subjective well-being status and to alter or modify future survivorship care plans for the 
survivors. Providing tailored interventions could improve HRQOL for those who have 
potential risk factors for poorer HRQOL. However, in order to tailor these interventions, 
a better understanding of factors associated with HRQOL among childhood cancer 
survivors is needed. This study addressed these gaps in the literature. In the next chapter 
a review of the methods used in this study are reported.
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CHAPTER III  
RESEARCH DESIGN AND METHODS 
 
 
Design  
 The secondary analysis in this study was designed to examine the effects of 
symptom clusters on health-related quality of life (HRQOL) among survivors of 
childhood cancer. This study used a cross-sectional design to identify factors that are 
related to HRQOL. The dynamic symptom model (Brant et al., 2016) guided the choice 
of variables including antecedents and outcomes, as well as the analyses. 
 This overall study aim was to investigate the association between symptom 
subgroup membership and HRQOL among survivors of childhood cancer in the St. Jude 
Lifetime Cohort (SJLIFE) study after controlling for type of childhood cancer and 
treatment modalities as well demographic characteristics (see Figure 2). The SJLIFE data 
included individuals who were diagnosed with a variety of types of cancer and received 
various treatments. Prior research using clustering techniques on cancer symptoms has 
identified several distinct subgroups of adults with cancer (Dodd et al.,2010 ; Kim et al., 
2012; Kim et al., 2014; Miaskowski et al., 2006). It was anticipated that using a similar 
technique with childhood cancer survivors would yield a similar outcome in terms of 
cluster structure. Key terms related to the analysis are defined below.  
Subgroups (also called subgroup memberships, clusters or classes) were defined 
as groups of individuals who are similar in their patterns on the indicator variables (i.e., 
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symptoms classes). Unlike traditional cluster analyses (such as hierarchical cluster 
analysis or K means cluster analysis) in which individuals are assigned to one and only 
one subgroup, mixture modeling is based on assigning subgroup membership for each 
individual based on the probability model. Indicator variables were defined as the 
variables analyzed to identify the subgroup membership. In this study, the indicator 
variables are binary, and indicate if the individuals experienced physical and 
psychological symptoms. These variables are illustrated by Y in Figure 2. Mixture 
modeling refers to a type of latent variable analysis in which the analyst strives to identify 
subgroup memberships. Two main forms of mixture modeling are latent class analysis 
(LCA: in which the indicator variables are binary - as in this study) and latent profile 
analysis (LPA: in which the indicator variables are continuous) (Masyn, 2013).  
The approach outlined below yielded 1) identification of subgroups of survivors 
of childhood cancer based on symptoms, 2) associations between demographic and 
clinical predictors of symptom subgroup membership, 3) associations between subgroup 
membership and HRQOL, and 4) the moderating effects of subgroup membership 
between predictors and HRQOL. Four specific sub-aims follow: 
Aim A: to identify homogenous subgroups of survivors who share common profiles 
across multiple symptoms including pain, cardiac and pulmonary symptoms, 
disfigurement, learning/ memory problems, and psychological symptoms (i.e., anxiety, 
depression, somatization, and global distress). 
Aim B: to examine demographic and clinical factors as predictive of subgroup 
memberships.  
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Aim C: to examine the differences of HRQOL as measured by two components of the 
SF-36 (physical function and mental function) between subgroup membership (identified 
above) and  
Aim D: to examine whether the subgroup membership moderate the relationship between 
predictors and HRQOL.   
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Figure 2  
 
Latent Class Moderation Analysis  
 
Each figure shading based on Aim A, B, C & D 
Class: a latent variable which holds class membership values for each participant 
X: predictor variables which were categorical or continuous (e.g., gender, age, & type of 
cancer)  
Y : indictor variables which were binary variables or continuous (e.g., pain, cardiac 
symptoms, pulmonary symptoms, & anxiety) 
Z: a distal outcome (e.g. HRQOL) which were continuous  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Used by permission from Dr. Patrick Curran 
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Setting and Participants 
 Participants.  
 SJLIFE was established as a retrospective cohort with continuous enrollment to 
better understand health status and severity of long-term late effects of treatments for 
childhood cancer survivors (Hudson et al., 2011). Survivor participants were diagnosed 
with childhood cancer and were treated between 1962 and 2002 at St. Jude Children’s 
Research Hospital. The SJLIFE study includes individuals who were 18 years or older at 
enrollment, and who had lived more than 10 years after cancer diagnosis.  
 Eligibility.  
 Inclusion criteria for the current study were : (1) diagnosis of childhood cancer 
treated at St. Jude Children’s Research Hospital (SJCRH); (2) survival of more than 10 
years since diagnosis; (3) 18 years or older at enrollment in the SJLIFE cohort study; and 
(4) between 10 and 19.9 years of age at that time of cancer diagnosis. The SJLIFE Study 
initiated enrollment of participants in November, 2007 (See. Figure 3. Project Consort).  
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Figure 3  
Project Consort  
 
Potentially Eligible
5 Year Cancer Survivor
(n = 9,698)
SJLIFE Cohort
Potentially Eligible for 
Assessment (n = 7,791)
Eligible for 
Symptom Study
(n = 5,085)
Non-Participants
(n = 767)
Active refusals (n = 399)
Passive refusals (n = 227)
Lost to followup (n =141)
Interested, 
participation pending
(n = 867)
Awaiting visit/survey      
(n = 549)
On hold/deferral           
(n = 318)
Participants
(n = 3,451)
Campus visit (n = 3,214)
Survey only (n = 237)
Final eligible 
participants
(n=3,129)
Excluded non-cancer 
patients (n=37),
Excluded surgery           
5 yrs after dx  (n=10), 
Missing data (n=10)
No survey (n = 31)
Proxy surveys  
(n = 234)
Eligible 
participants                
(n = 3,186)
Died prior to participation (n = 988)
Alive, not yet recruited (n = 816)
Consented only (n = 469)
Ineligible for symptom study: less 
than 10 year survival OR under 18 
years of age as of data freeze OR 
diagnosed at age 20+ years (n = 433)
Ineligible (n=137) 
Eligibility not yet determined 
(n = 1770) 
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Procedures 
Data Information.   
When the SJLIFE data were collected, participants were surveyed using SJLIFE 
questionnaires about demographics, symptom experiences, and patient outcomes (i.e., 
brief symptom inventory [BSI]-18 and the medical short form of outcome [SF-36]). 
Clinical variables (types of cancer, types of treatment, age at cancer diagnosis, and 
secondary cancer) were generated through St. Jude’s medical records and SJLIFE 
research databases (Dr. Huang, personal communication, June 23, 2017). 
Instruments.   
Based on the Dynamic Symptoms Model (Brant et al., 2016), each instrument is 
represented below under either antecedents; symptoms; or consequences.  
Antecedents.    
a. Demographic variables  
 Age at survey (years): 18-29, 30-39, ≥ 40 
 Gender: male and female  
 Race/ethnicity: non-Hispanic White, non-Hispanic Black, Hispanic, and 
Other  
 Educational background: less than high school diploma, high school 
graduate/ General Education Development (GED), some college/training 
after high school, and more than college graduate 
 Marital status: married and living with a 
partner/widowed/divorced/separated/single 
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 Employment status: currently employed (full/part time) and currently 
unemployed 
 Insurance status: insured and uninsured 
 Had difficulty obtaining health insurance: yes and no  
 Annual household incomes: ≤ $39,999, $40,000-$79,999, and ≥ $80,000 
 Annual personal incomes: none, $1 to ≤ $19,999, $20,000 to ≤ $59,999, 
and ≥ $60,000 
b. Clinical variables  
 Cancer diagnoses: All diagnoses related to pediatric cancers: Leukemia, 
Central nervous system tumors, Hodgkin’s lymphoma, Non-Hodgkin’s 
lymphoma, Sarcoma, Embryonic tumors, Bone tumors, and others   
 Time since diagnosis in years 
 Age at diagnosis (years): 0-4 years, 5-9 years, ≥ 10 years 
 Cancer treatment.   
 Chemotherapy: none; corticosteroids; Mercaptopurine/Thioguanine; 
Methotrexate; Erwinia-/ L-/ Peg-asparaginase; 
cisplatin/carboplatin/oxaliplatin; alkylating agents; anthracyclines; 
vincristine; other agents (all with yes/ no)  
 Radiotherapy: none; head/neck area; chest/lung area; 
pelvis/abdominal/urinary area; reproductive area (male/female); and 
other areas (muscle area)  
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 Surgery: yes (invasive surgery: that are only related to cancer-related 
treatment, includes surgery within 5 years since cancer diagnosis)    
Symptom Perception.  
c. Physical/ psychological symptoms  
Physical and psychological symptoms in the SJLIFE study include nine physical 
symptoms and three psychological symptoms. From the comprehensive health 
questionnaire administered to the SJLIFE participants, 41 items measuring human organ 
impairment were categorized into nine physical symptoms (as indicators) and three 
psychological symptoms (as indicators). Each item has three response categories (“yes, 
the condition is still present,” “yes, but the condition is no longer present,” and “no”). 
Symptom presence was denoted if participants endorsed “yes, the condition is still 
present” for any item measuring that particular symptom. The physical symptoms 
included: cardiac symptoms (3 items); pulmonary symptoms (3 items); motor/movement 
problems (5 items); pain in head (3 items); pain in back/neck (2 items); pain involving 
sites other than head, neck, and back (7 items); sensation abnormalities (10 items); 
disfigurement (7 items); and learning/memory problems (1 item). Three psychological 
symptoms included: anxiety (6 items), depression (6 items), and somatization (6 items) 
based on the brief symptom inventory-18 (BSI-18). A summated item score of a 
particular symptom class was calculated and converted into an age and sex specific T-
score; a score ≥ 63 was used to identify presence of a symptom class. 
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 Consequences.  
 
 Health-related quality of life. The Medical Outcomes Short form-36 (SF-36) 
instrument was used to measure HRQOL. This measure is composed of 36 questions 
assessing functioning and well-being in physical, mental, and social dimensions of life 
(Ware, Kosinski, Dewey, & Gandek, 2000). This instrument has eight domains of 
HRQOL including physical functioning (10 items); role-limitation due to physical health 
problems (4 items); bodily pain (2 items); general health perceptions (5 items); vitality (4 
items); social functioning (2 items); role-limitation due to emotional health problems (3 
items); and general health (5 items). These eight domains can be summed into two 
measures: the physical component summary scores (PCS) and mental component 
summary scores (MCS). These two summary scores were used to evaluate overall 
physical and mental functioning of HRQOL. The sum of the scores was scaled from 0 to 
100, with higher scores representing better HRQOL.  
Data Management   
Protection of Human Subjects.   
 The SJLIFE protocol and survey questionnaires were approved by the SJCRH 
Institutional Review Board (IRB). Informed consent was obtained from all participants 
before starting data collections. This current study was approved by University of North 
Carolina at Greensboro IRB (number: 16-0450) and was determined to be exempt from 
further review according to a regulatory category since this study used de-identified 
secondary data.  
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Data Safety and Monitoring.   
 The original survey documents are stored in a double-locked cabinet in the 
Department of Epidemiology and Cancer Control at St. Jude Children's Research 
Hospital. The electronic survey data were de-identified and stored on secured research 
servers at St. Jude Children’s Research Hospital. In order to access the electronic 
survey data, an individual needs to get permission from the data management team and is 
required to use password and ID protected computers to access the research servers. Data 
analyses for this study were primarily conducted at St. Jude Children’s Research 
Hospital. Follow up analyses were performed on SJLIFE de-identified data at the 
University of North Carolina at Greensboro.  
 Data Management and Analysis.  
 SAS version 9.4 (SAS Institute Inc., Cary, North Carolina) and SPSS version 23.0 
(SPSS INC., Chicago, IL) software were used in data preparation and management. 
Mplus version 8.0 (Phoenix Flow Systems, San Diego, CA) software was primarily used 
for data analyses. The samples were described using descriptive statistics. Frequencies 
were used for nominal level data, and means and standard deviations were calculated for 
continuous and interval data.  
 Data Cleaning.   
The raw data consisted of data on all variables for 3,189 participants who met the 
inclusion criteria (see Figure # 3). A codebook was developed that included frequencies 
of all variables from the original survey data. The codebook included six sections (e.g., 
section I. demographics: types of cancer, gender, race, age at survey, age at enrollment, 
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years at diagnosis, live with whom, ever married, education, employment, home income, 
personal income, financial status at the end of the month, and had difficulty obtaining 
health insurance; section II. symptom (indicator variable): hair loss, scarring on the body, 
walk with a limp, problems with double vision, abnormal sense of taste, arrhythmia, 
angina pectoris, chronic cough, emphysema, breathing problems, tremor, problems of 
balance, headache, body image, sensation, movement, cardiac problems, pulmonary 
problems, pain, memory, depression, anxiety, somatization, and HRQOL questionnaire 
using SF-36 ; section III. treatment modalities: chemotherapy (anti-tumor antibiotics, 
carboplatin, cisplatin, corticosteroids, cytarabin, doxorubicin, erwinia asparaginase, high 
dose methotrexate, L-asparaginase, mercaptopurine, oxaliplatin, thioguanine, and 
vincristine), radiation therapy (abdomen, breast, chest, eye, ear, female, male, GI hepatic, 
lung, muscle, oral, pelvis, urinary, and total body irradiation), surgery, and secondary 
cancer; section IV. Psychological distresses (Brief Symptom Inventory-18); section V. 
health behaviors (ever smoked, tobacco, marijuana/Hashish/Cannabis use, number of 
years use tobacco, drinking, vigorous exercise, moderate exercise, limited exercise, and 
sun protective behavior); and section VI. Motivation (four motivation behaviors, 10 social 
desirability, and five worry about cancer treatment complications). Section V and VI 
were not be used for the current project and will be used another project to examine 
moderated mediating effects using psychological factors among treatment variables, 
health behaviors, and symptoms in survivors of childhood cancer.  
 Variables were regrouped based on characteristics of participants such as types of 
cancer, race/ethnicity, and age at survey. Non-cancer patients (n = 37) were excluded as 
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were 10 patients who did not meet the inclusion criteria regarding their surgery history. 
At the beginning, 3,139 participants were used for the data analyses. Using Mplus, when 
the number of subgroups was chosen regarding Aim A, 10 participants were 
automatically deleted due to missing values. Thus, 3,129 participants were retained for 
this current study.  
Analytic Approach for the Aims  
 The proposed analytical approach to accomplish the four sub aims of this study 
employed a four-phase model fitting process. It should be noted at the outset that the 
model fitting, especially in the first phase (aim A), required stepwise approaches for 
testing multiple models to arrive at the “best” model before going to the next phase. 
Model fitting relied on the recommendations of a number of methodologists for best 
practices in model fitting (Asparouhov & Muthén, 2014; Marsh, Lüdtke, Trautwein, & 
Morin, 2009; Masyn, 2013; Pastor, Barron, Miller, & Davis, 2007). Mplus (version 8.0) 
was used for the majority of the analyses such as finding the best model, conducting 
bivariate analyses, and conducting multivariable analyses. Given this overview, 
definitions of specialized terms used in the analyses, then the analytical plan for each sub 
aim, are provided.  
 Analyses for Aim A.   
A strength of mixture modeling is that the modeling provides posterior profiles of 
membership in the subgroups instead of a rigid assignment of individuals to one and only 
one class (Masyn, 2013). Thus, the mixture model is more flexible in fitting models in 
which the data are not necessarily structured in a hierarchical fashion. In addition, the 
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mixture modeling also provides several probability-based tools for deciding on the 
number of classes to retain, tools which are not available in traditional hierarchical 
clustering methods. Finally, recent development in mixture modeling provides for the 
modeling of predictors of subgroup membership and distal outcomes (conditioned on 
subgroup membership) into a single joint model. This final point is an additional benefit 
of using mixture modeling in nonhierarchical data sets. There is considerable 
methodological work on this approach (Clark & Muthén, 2009; Vermunt, 2010; Wang, 
Hendricks Brown, & Bandeen-Roche, 2005). This mixture modeling provides a method 
for testing joint models which are homologous with the aims of this current study as in 
the model provided in figure 2. In figure 2 the LPA model (Aim A), a model of predictors 
of subgroup membership (Aim B), a model to examine the differences in distal outcomes 
based on subgroup membership (Aim C), and a model to examine the moderating effects 
of the subgroup membership on the relationship between predictors and HRQOL (Aim 
D) are presented.   
The methodological issues that arise in this modeling have to do with the 
influences of the predictors and the outcomes on the analyses of subgroup memberships. 
It is common to see that subgroup memberships change with the addition of extra 
information contained in the predictors and outcomes, and such changes may undermine 
the validity of the initial mixture analyses. One solution is to use the Vermunt’s three-
step approach, which is implemented within Mplus software. This approach fixes 
subgroup membership by assigning individuals to the subgroup for which the posterior 
probabilities are highest. This discrete variable is then used as the indicator of group 
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membership (in place of the original indicators as shown in figure 2). The results of 
simulation using Vermunt’s three-step approach indicated that this approach retains the 
validity of the original mixture model while providing for the benefits of testing 
hypotheses about predictors and outcomes of group membership. 
The process of fitting the latent class model to the data was conducted by 
minimizing the likelihood function based on the number of clusters proposed. The 
process started with a baseline model with one cluster and then subsequently was 
expanded to two, three ... K clusters. At each model, a series of fit indices (AIC, BIC, and 
Sample size adjusted BIC) were examined and used to aid in the identification of the best 
model. In addition to these fit indices, the Lo Mendell Rubin test was used to test the 
hypotheses that the K number of classes provided a better fit that the K-1 model 
(Asparouhov & Muthén, 2014).  
In addition to the fit indices, it was important to examine the size of the 
subgroups. For example, subgroups of less than 5% of the total sample may not have 
been reliable and thus size of subgroup is an important consideration in this phase of 
model fitting. Note that in cases with poor separation, these processes may not be 
definitive and one must rely on interpretability such as percent in each cluster (Marsh et 
al., 2009). Once the “best” model is obtained, the class membership becomes available 
for analyses either as a dependent variable or a predictor variable (see aim B and C).  
 Analyses for Aims B and C.    
In addition to the methodological work concern of establishing the “best” model 
as described above, there has been considerable methodological work in the best ways to 
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examine predictors of subgroup membership and to examine outcomes of subgroup 
membership. One concern in this type of modeling is that by including predictors or 
outcomes of subgroup membership, the composition of the subgroups can shift (and thus 
introduce measurement error in the model and potentially invalidate the model developed 
in Aim A). The issue with regard to predicting distal outcomes based on cluster 
membership is related to circularity – the distal outcome inadvertently becomes an 
indicator variable at the same time it serves as an outcome variable.  
To address this issue, Aspoarouhov and Muthén (2014) have summarized the 
work of a number of methodologists (e.g. Vermunt, Lanza, and Baak). These authors 
have explicated a strategy for the study of predictors and outcomes of subgroup 
membership and have implemented these strategies within Mplus. In Aim B and Aim C, 
the recommendations by Aspoarouhov and Muthén (2014) were followed and employed 
Vermunt’s three-step approach. The Vermunt’s three step approach can set up predictors 
and outcome variables separately. This work has been seen as a significant improvement 
over previous approaches which have built into a single modeling approach either the 
predictors of subgroup membership or employing subgroup membership as a predictor of 
distal outcomes.  
Analyses for Aim D.   
Whereas the test statistics for models Aim A through Aim C are provided as fit 
indices, the bootstrap Lo Mendell Rubin (model Aim A) regression coefficients for 
multinomial logistic regression (model Aim B) and tests of distal outcome means across 
groups (model Aim C), and the test for the moderating effect of group membership on the 
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association between clinical and demographic characteristics and distal outcomes (model 
Aim D) are accomplished using the Wald test. This test proceeds by constraining the 
regression coefficients of the predictors for each subgroup to be equal, and then testing 
the equality of these regression coefficients by examining differences in fit between the 
constrained and unconstrained model.   
Reporting Methods of Aims  
Aim A.  
Aim A is to identify subgroup membership of survivors who share common 
profiles across multiple symptoms (See Figure 2). The methods described above for the 
critical step of identifying the number of subgroups that provide the best fit to the data 
were employed. Multiple models were contrasted by selecting indicator variables which 
provided the clearest separation between subgroups and the greatest homogeneity within 
groups.    
Reporting method: This model was reported in several ways. The most salient 
report is a graph of the indicator means (proportions) across subgroups. Additional results 
in the form of fit indices that were used to justify the decision about the number of 
subgroups were provided. The AIC, BIC, and SSA BIC, and the Bootstrapped Lo 
Mendell Rubin Test (AIC: Akaike's Information Criterion, BIC: Bayesian Information 
Criterion, SSA-BIC: Sample-size-adjusted Bayesian Information Criterion) were 
employed. 
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Aim B.  
Aim B is to examine demographic and clinical predictors of subgroup 
membership (See Figure 2). In this aim, predictors of subgroup membership were 
examined using the recommended Vermunt’s three-step approach as discussed above. 
The analyses were focused on the main effects. Although the modeling could include 
interaction effects, this was not the focus on the current study. Thus, only the main effects 
were analyzed. Finding factors could provide a basis for refining the model and 
subsequent development of individualized interventions for vulnerable groups in an early 
period of cancer survivorship.   
Reporting method: the analyses consisted of a series of simple logistic regression 
models in which class membership served as the binary outcome. These simple logistic 
models were followed by a multivariable logistic model in which those predictors which 
were associated with the p value of less than or equal to .001 were included as predictors.  
Multinomial regression analysis was conducted to address the issue of the dependent 
variable and subgroup membership if the numbers are greater than two. The primary 
reporting method is a table of values of the odd ratios accompanied by 95% confidence 
intervals. 
Aim C.  
Aim C is to examine the HRQOL differences between subgroup memberships 
(See Figure 2). The association between subgroup membership and the distal outcome of 
HRQOL was examined. As discussed above, the Vermunt’s three-step approach within 
Mplus was used. It was expected that these analyses would include a multinominal 
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predictor variable (subgroup membership) and a continuous outcome variable (the 
medical short form - 36 [SF-36]). In Aim c, the analysis provided tests of mean 
differences of HRQOL across the classes comparable to analysis of variance.  
Reporting method: The results of these analyses were reported in tabular form and 
may be thought of as a series of cross tabulation analyses with the chi-squared test 
statistic as the basis for hypothesis testing (See Table 6). Multivariable analyses were 
used to examine the relationships between predictors and the physical component 
summary HRQOL (PCS) (Table 7) and between predictors and the mental component 
summary HRQOL (MCS) (Table 8). 
 Aim D.  
Aim D is to examine whether the subgroup membership moderate the relationship 
between predictors and HRQOL (See Figure 2). Using the Vermunt’s three-step 
approach, the moderating effects of the symptom subgroups between predictors and 
HRQOL were examined. Common predictors between physical HRQOL and mental 
HRQOL were chosen and the Wald test was used to conduct hypothesis testing about the 
moderating effect of subgroup membership on the relationship between clinical and 
demographic predictors and the distal outcome. 
Reporting method: The results of these analyses were reported (See Table 9).   
Summary of Research Design and Methods  
In this chapter, inclusion criteria of participants, settings, and measurements were 
provided. The measurements included antecedents (demographic variables and clinical 
variables), symptom perceptions, and consequences (HRQOL). Also, data management 
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and analysis plans for each research question were provided. In order to support better 
understanding about the four sub-aims, a diagram was provided. In the next chapter, 
findings of the statistical analyses and testing of each research question are described. 
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CHAPTER IV 
 
RESULTS 
 
The purpose of this study was to investigate the association between subgroup 
membership based on effect of late effects on HRQOL using cluster mixture modeling. 
This chapter reports the results of the statistical analyses used to evaluate the complex 
mixture model as outlined in the previous chapter. This chapter proceeds as follows: the 
report of the sample characteristics; the results of the initial mixture modeling 
(Hypothesis A); prediction of subgroup membership by demographic and clinical 
characteristics (Hypothesis B); tests of subgroup membership differences in physical and 
mental functioning (Hypothesis C); and a test of the association between clinical and 
demographic variables with physical and mental functioning as moderated by subgroup 
membership (Hypothesis D).     
Sample Characteristics  
This is a report of a secondary data analysis using SJLIFE cohort study data. The 
total sample size was 3,129 long-term survivors of childhood cancer. Table 1 shows the 
demographic and clinical characteristics of the survivors of childhood cancers in this 
study.  
Demographic Variables.   
The mean age of the study participants at the time of interview was 31.9 years 
(SD = 8.4 years) and the mean age at cancer diagnosis was 8.45 years (SD = 5.5 years). 
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The mean time since cancer diagnosis was 28.10 years (SD = 9.1). Among the 
participants, the percentage of males and females were similar at about 50%. Most 
participants were non-Hispanic White (n = 2,408, 79.8%) and the next largest population 
was non-Hispanic Black (n = 395, 13.1%). Most participants reported that they were 
college graduates (n = 2,055, 71.5%). In particular, 36% of survivors (n = 1,034) had 
more than a college degree. Half of the participants were married (n = 1, 298). Sixty 
seven percent of survivors (n = 2,057) currently work full-time or part-time. Most 
participants had insurance (n = 2,327, 77.7%), and most participants had no difficulty in 
obtaining insurance (n = 2,238, 75.4%). About forty percent of survivors had either low 
income ($1 to ≤ $19,999) or middle income ($20,000 to $59,999). In particular, about 
13% of survivors (n = 381) had no income.  
Clinical Variables.  
Participants had various types of childhood cancer, which were categorized into 
four groups: leukemia, lymphoma, sarcoma, and central nervous system tumors. The 
number of patients who were diagnosed with each type of cancer were as follows: 
leukemia (n = 1,166, 37.3%), sarcoma (n = 1,029, 32.9%), lymphoma (n = 631, 20.2%), 
and central nervous system tumors (n = 303, 9.7%). Acute lymphoblastic leukemia, acute 
myeloid leukemia, and other types of leukemia were grouped as “leukemia.” Hodgkin’s 
lymphoma and non-Hodgkin’s lymphoma were grouped as “lymphoma.” Also, 
“sarcoma” included Ewing’s sarcoma, osteosarcoma, rhabdomyosarcoma, 
neuroblastoma, Wilms’ tumor, and bone tumors. Among participants, 15.4% of survivors 
(n = 425) experienced secondary cancer. Participants who experienced a surgery 
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accounted for 70.7% (n = 2,211), more than 70% of participants were treated with 
chemotherapy (n = 2,429), and 60% of survivors had been treated with radiotherapy (n = 
1,819).   
Several types of chemotherapy were used by more than 50% of the participants. 
These included: corticosteroids (n = 1,472, 47.1%), mercaptopurine/thiouguanine               
(n = 1,943, 62.1%), methotrexate (n = 1,608, 51.4%), anthracycline (n = 1,833, 58.7%), 
alkylating agents (n = 1,834, 59.2%), and vincristine (n = 2,124, 68.6%). Regarding 
radiotherapy, treatment in the head/neck area was the most prevalent (n = 1,537, 49.1%). 
Nearly 30% of participants received radiotherapy to other areas including chest/lung, 
pelvis/abdomen/urinary, and reproductive areas.  
 
Table 1 
 
Demographic, Clinical Characteristics of Survivors of Childhood Cancers 
 Variable  Total Sample 
(N=3,129) 
M (SD) 
Age at interview [in year] 31.9  (8.4) 
Age at cancer diagnosis (mean, SD) [in years] 8.45  (5.5) 
Time since cancer diagnosis, (mean, SD) [in years] 28.10 (9.1) 
 n (%) 
Sex  
  Male 1,583 (50.6) 
  Female 1,544 (49.4)  
Race/ethnicity  
  White, non-Hispanic 2,408 (79.8) 
  Black, non-Hispanic 395   (13.1) 
  Hispanic 144    (4.8)  
  Other  70      (2.3) 
Educational background  
  Less than high school diploma 261   (9.1) 
  High school graduate/ GED  556   (19.4) 
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  Some college/ training after high school 1,021 (35.5) 
  College graduate/ Post graduate level 1,034 (36.0) 
Marital status  
  Married 1,298 (42.6) 
Living with a partner/ widowed/ divorced/ 
separated/single 
1,750 (57.4) 
Employment status  
  Currently employed (Full/part time)  2,057 (66.8) 
  Currently unemployed 1,034 (33.2) 
Insurance status  
  Insured 2,327 (77.7) 
  Uninsured 668   (22.3) 
Had difficulty obtaining health insurance  
   No 2,238 (75.4) 
   Yes 729   (24.6) 
Annual personal income   
  None 381   (12.7) 
  $1 to ≤$19,999 1,197 (39.9) 
  $20,000 to $59,999 1,103 (36.8) 
  ≥$60,000 318   (10.6) 
Annual household income  
  ≤$39,999 1,141 (43.7) 
  $40,000 to $79,999 853   (32.7) 
  ≥$80,000 616   (23.6) 
Cancer diagnosis   
  Leukemia  1,166 (37.3) 
  Central nervous system tumor  303   (9.7) 
  Lymphoma          631   (20.2) 
  Sarcoma      1,029 (32.9) 
  Secondary cancer  
  No 2,339 (84.6) 
  Yes 425   (15.4) 
Chemotherapy  
  Any chemotherapy 2,429 (77.6) 
  Corticosteroids 1,472 (47.1) 
  Mercaptopurine/Thioguanine 1,943 (62.1) 
  Methotrexate 1,608 (51.4) 
  Erwinia-/ L-/ Peg-asparaginase 1,017 (32.4) 
  Cisplatin/carboplatin/oxaliplatin 384   (12.3) 
  Anthracycline 1,833 (58.7) 
  Alkylating agents  1,834 (59.2) 
  Vincristine 2,124 (68.6) 
  Other agents  1,731 (55.3) 
  
71 
 
Radiotherapy  
  Any radiotherapy 1,819 (58.3) 
  Head/neck area  1,537 (49.1) 
  Chest/lung area 931   (29.8) 
  Pelvis/abdominal/urinary area 1,005 (32.1) 
  Reproductive area  665   (21.3) 
  Muscle area 1,145 (36.6) 
Invasive surgery 2,211 (70.7) 
Note. Leukemia includes (Acute lymphoblastic leukemia, acute myeloid leukemia, & 
other leukemia); Lymphoma includes (Hodgkin’s lymphoma & non-Hodgkin’s 
lymphoma); Sarcoma includes (Ewing’s Sarcoma, osteosarcoma, rhabdomyosarcoma, 
neuroblastoma Wilms’ tumor, & bone tumors) 
 
 
Subgroup Differences in Demographic and Clinical Variables.   
The majority of the variables except race, surgery, and certain types of 
chemotherapy were significantly different between the two subgroup memberships, as 
shown below in table 2. The following analyses were conducted on the clusters in order 
to examine their differences. Cluster membership was used as the independent variable 
(with other demographic and clinical variables) in order to examine the differences 
between the symptom clusters on the demographic and clinical variables.   
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Table 2 
 
Subgroup Differences in Demographic and Clinical Characteristics  
Variable  High 
symptoms 
cluster  
Low 
symptoms 
cluster 
Test, Statistical 
Significance 
 n=888 
(29.4%) 
n=2,241 
(71.6%) 
  
 M (SD) M (SD) F p 
Age at interview [in year] 33.45 (8.3) 31.33 (8.3)  2978.28  0.474 
Age at cancer diagnosis (mean, SD)  
[in years] 
9.02   (5.6) 8.24   (5.5) 2897.84  0.424 
Time since cancer diagnosis (mean, 
SD) [in years] 
29.26 (9.3) 27.69 (9.0) 81.62 0.0003 
 n  (%) n (%) 𝜒2 p 
Sex     
  Male 382 (45.3) 1,201 (52.5) 13.02 <0.001 
  Female 461 (54.7) 1,083 (47.4)   
Race/ethnicity     
  White, non-Hispanic 664 (81.8) 1744 (79.1) 5.27 .153 
  Black, non-Hispanic 104 (12.8) 291 (13.2)   
  Hispanic 28   (3.45) 116 (5.3)   
  Other  16   (1.97) 54   (2.5)    
Educational background     
  Less than high school diploma 118 (15.3) 143 (6.8) 89.45 <0.001 
  High school graduate/ GED  186 (24.1) 370 (17.6)   
  Some college/ training after high 
school 
270 (34.9) 751 (35.8)   
  College graduate/ Post graduate 
level 
199 (25.7) 835 (39.8)   
Marital status     
  Married 311 (36.9) 987   (43.2) 6.97 .008 
Living with a partner/ widowed/   
divorced/ separated/single 
494 (58.6) 1,256 (54.9)    
Employment status     
  Currently employed (Full/part time)  411 (48.8) 1,646 (72.0) 150.97 <0.001 
  Currently unemployed 418 (49.6) 616 (26.5)   
Insurance status     
  Insured 590 (73.3) 1,737(79.3) 12.32 <0.001 
  Uninsured 215 (26.7) 453 (20.7)   
 
Had difficulty obtaining health 
insurance 
    
   No 517 (65.5) 1,718 (79.1) 61.84 <0.001 
   Yes 272 (34.5) 453 (20.9)   
Annual personal income      
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  none 135 (16.7) 246 (11.2) 78.43  <0.001 
  $1 to ≤$19,999 397 (49.0) 800 (36.6)   
  $20,000 to $59,999 225 (27.8) 878 (40.1)   
  ≥$60,000 53   (6.5) 265 (12.1)   
Annual household income     
  ≤$39,999 427 (61.4) 714 (37.3) 124.04 <0.001 
  $40,000 to $79,999 169 (24.3) 684 (35.7)   
  ≥$80,000 99   (14.2) 517 (27.0)    
Cancer diagnosis      
  Leukemia  306 (26.3) 860 (37.6) 28.70 <0.001 
  Central nervous system tumor  105 (12.5) 198 (8.7)   
  Lymphoma          202 (24.0) 429 (18.8)   
    Sarcoma      230 (27.3) 799 (35.0)   
Secondary cancer     
  No 613 (81.3) 1,717 (85.8) 10.19 .006 
  Yes 141 (18.7) 284 (14.2)   
Chemotherapy     
  Any chemotherapy 676 (80.2) 1,753 (76.7)  4.36 .037 
  Corticosteroids 412 (48.9) 1,060 (46.4)  1.55 .213 
  Mercaptopurine/Thioguanine 328 (38.9) 858 (37.5) 0.50 .482 
  Methotrexate 428 (50.8) 1,180 (51.6) 0.17 .674 
  Erwinia-/ L-/ Peg-asparaginase 264 (31.3) 753 (32.9) 0.74 .390 
  Cisplatin/carboplatin/oxaliplatin 122 (14.5) 262 (11.5) 5.19 .023  
  Anthracycline 542 (64.3) 1,291 (56.6)  15.32 <0.001 
  Alkylating agents  543 (65.0) 1,291 (57.0) 16.19 <0.001 
  Vincristine 587 (70.1) 1,537 (67.9) 1.76 .185  
  Other agents  472 (56.0) 1,259 (55.1)  0.21 .647 
Radiotherapy     
  Any radiotherapy 570 (67.7) 1,249 (54.8) 42.34 <0.001 
  Head/neck area  497 (59.0) 1,040 (45.5) 44.66 <0.001 
  Chest/lung area 310 (36.8) 621 (27.2) 27.20 <0.001 
  Pelvis/abdominal/urinary area 325 (38.6) 680 (29.8)  21.91 <0.001 
  Reproductive area  216 (25.6) 449 (19.6)  13.17 <0.001 
  Muscle area 364 (43.2) 781(34.2)  21.57 <0.001 
Invasive surgery 613 (72.7) 1,598 (69.9) 2.35 .125 
Note. Leukemia includes (Acute lymphoblastic leukemia, acute myeloid leukemia, & other 
leukemia); Lymphoma includes (Hodgkin’s lymphoma & non-Hodgkin’s lymphoma); Sarcoma 
includes (Ewing’s Sarcoma, osteosarcoma, rhabdomyosarcoma, neuroblastoma Wilms’ tumor, & 
bone tumors) 
 
 
Results of Hypotheses Testing  
 This section outlines the results of hypotheses testing and findings. In most 
analyses, the Vermunt-three step approach using Mplus software program was employed.  
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Hypothesis A.  
 The hypothesis of Aim A stated that several meaningful subgroups of survivors 
with heterogeneous symptom patterns will be identified. This hypothesis was supported. 
Two distinctive groups based on ten symptoms were identified: a group with high 
symptoms and a group with low symptoms. These clusters were named the “high 
symptom cluster” and the “low symptom cluster.” In order to determine the best number 
of symptom clusters, Mplus was used. As previously mentioned in the methodology 
section, a series of fit indices (AIC, BIC, and Sample sized adjusted BIC) were used to 
identify the best model. The lowest values of each score were used as criteria to choose 
the best fit model (Asparouhov & Muthén, 2014).   
 When a four subgroup membership was chosen, the BIC (Bayesian Information 
Criterion), CAIC (Consistent Akaike information criterion), and SSA-BIC (Sample-size-
adjusted Bayesian Information Criterion) were the lowest. However, when the two-
subgroup membership was chosen, the CLC (Classification likelihood criterion) and ICL-
BIC (Integrated classification likelihood with BIC approximation) were also the lowest, 
and entropy was the highest (see Table 3). Figure 4 (Summary of Model Fit) showed the 
values of AIC, BIC, CAIC, SSA-BIC, CLC, and ICL-BIC. The two subgroups were 
chosen based on this result. Choosing the best cluster solution is perhaps the most 
demanding aspect of mixture modeling.  
The decision to choose the two-group solution was based on three criteria. The 
first was the pattern of decline (and rebound in the various fit statistics). With this 
criterion in mind researchers might choose either a two- or four-group solution. As can be 
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seen in Table 3, the BIC begins to rebound in the five-class solution, indicating that the 
four-class solution is a viable one, whereas the CLC rebounds at the two-class solution. 
Thus by these indices a solution between two and four classes seems viable. The second 
criteria is the Lo Mendell Rubin test, which shows that the four-class solution is also 
viable. The final criterion (and perhaps the most important criterion) is the interpretability 
of the class solution. Interpretability is not clear-cut, but may vary from research team to 
research team. Perhaps the clearest evidence for interpretability comes from the pattern of 
symptoms across the two-class solution which is discussed in the next section. The 
research team (committee members and author of this dissertation) decided to proceed 
with the two-cluster solution since this was indicated by the fit indices and the Lo 
Mendell Rubin test, and because this solution was deemed the most interpretable. 
 
Table 3  
 
Goodness of Fit for Models Based on Different Numbers of Groups  
 
C #P LL AIC BIC CAIC CLC 
Entro
py ICL-BIC 
 
p LMR 
(BLRT) 
1 10 -14783.80 29587.60 29648.08 29658.08 29567.60 NA 29648.08 
 
NA 
2 21 -13463.26 26968.51 27095.53 27116.53 27976.24 0.758 28145.26 
 
.0000 
3 32 -13291.09 26646.18 26839.73 26871.73 28541.59 0.715 28799.14 
 
.0000 
4 43 -13174.60 26435.20 26695.28 26738.28 28856.40 0.711 29202.48 
 
.0000 
5 54 -13134.44 26376.87 26703.49 26757.49 29320.65 0.697 29755.27 
 
.0137 
6 65 -13100.40 26330.81 26723.96 26788.96 30069.23 0.655 30592.39 
 
.1573 
    Note. C=Classes; #P=number of parameters; LL=Loglikelihood; AIC= Akaike's Information Criterion; 
BIC= Bayesian Information Criterion; CAIC= Consistent Akaike information criterion; 
CLC=Classification likelihood criterion; ILC-BIC=Integrated classification likelihood with BIC 
approximation; p LMR (BLRT)= p values for the Lo Mendell Rubin likelihood and the bootstrap 
likelihood ratio test for K vs. K -1 classes.   
  
76 
 
Figure 4  
 
Summary of Model Fit 
 
 
 
A. Pattern of symptom experience across the two clusters.  The pattern of 
symptoms in each subgroup was shown using both a scatter plot (Figure 5) and a table 
(Table 4) representing this result. When the four-subgroup membership was chosen, there 
was overlap between the ten symptoms, but in the two-subgroup solution, a clear 
distinction was shown between the levels of symptoms. Table 4 shows the pattern of 
symptom experience across the two clusters in long-term survivors of childhood cancer 
using Mplus. These means are a second representation of the means provided in the 
figure. Among all participants, pain was the most prevalent symptom (n = 2, 362, 75.5%) 
and half of participants had disfigurement (n = 1, 690, 55.0%). Also, sensation 
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abnormalities were highly prevalent (n = 972, 31.1%), and learning/memory problems 
were endorsed by 749 participants (24.3%). Several symptoms were reported by less than 
20% of participants, including motor/movement symptoms (n = 508, 16.3%) and cardiac 
symptoms (n = 471, 15.1%). Also, survivors who experienced psychological symptoms 
showed less than 20% prevalence, which included anxiety, depression, and somatization. 
There were significant differences between the two subgroup memberships (high 
symptoms cluster and low symptoms cluster) in each of the ten symptoms.  
 
Figure 5  
 
Pattern of Symptom Experience across the Two Clusters (using a graph) 
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Table 4  
Pattern of Symptom Experience across the Two Clusters (using a table) 
Note. Prevalence of symptoms in the total sample was calculated. The prevalence of symptoms in 
each subgroup (high and low symptom cluster) were calculated separately. The total sample’s 
symptoms prevalence were different from the sum of the high symptom cluster and the low 
symptom cluster.  
 
 
Hypothesis B.  
Hypothesis B stated that demographic or clinical factors would differentially 
predict subgroup membership. This hypothesis was supported. Bivariate analyses were 
used to examine the relationships between each demographic and clinical variable and 
subgroup memberships. Most variables were significant in each subgroup, except for 
Individual Symptom Group Prevalence n (%) 
 
 Total 
Sample 
High 
symptoms 
cluster  
Low 
symptoms 
cluster 
𝜒2 p 
 N = 3,129 n=888 
(28.4) 
n=2,241 
(71.6) 
  
Cardiac symptoms  
(yes/no) 
471 (15.1) 315 (37.4) 156 (6.9) 448.29 <.0001 
 
 Pulmonary symptoms  
(yes/no) 
183 (5.9) 145 (17.4) 38 (1.7) 271.92 <.0001 
 
 Motor/movement problems  
(yes/no)  
508 (16.3) 396 (47.1) 112 (4.9) 801.14 <.0001 
 
 Pain  
(yes/no) 
2362 (75.5) 821 (97.4) 1541 (67.4) 298.73 <.0001 
 Sensation abnormalities  
(yes/no) 
972 (31.1) 569 (67.5) 403 (17.7) 713.06 <.0001 
 
 Disfigurement  
(yes/no) 
1690 (55.0) 591 (71.7) 1099 (48.8) 127.79 <.0001 
 
 Learning/memory problems  
(yes/no) 
749 (24.3) 399 (48.3) 350 (15.5) 353.13 <.0001 
 
 Anxiety  
(cutoff: 63) 
368 (12.1) 336 (40.9) 32 (1.4) 884.60 <.0001 
 
 Depression  
(cutoff: 63) 
465 (15.2) 387 (47.0) 78 (3.5) 884.50 <.0001 
 
 Somatization  
(cutoff: 63) 
554 (18.1)  506 (61.4) 48 (2.2)  1426.16 <.0001 
 
  
79 
 
race. After conducting bivariate analyses between all demographic and clinical variables 
and symptom variables, 18 statistically variables were chosen for multivariable analysis. 
Table 5 (Associations of symptom subgroups with demographics and clinical variables) 
represents this result.  
B1. Demographic characteristics as predictors of cluster membership (using 
bivariate analyses). Participants who were more than 40 years old at the time of survey 
were 1.92 times (95% CI [1.49, 2.48]) as likely to be in the high symptom cluster group 
compared to participants between 18-29 years old at the time of the survey. Participants 
who had survived more than 30 years since cancer diagnosis were 1.45 times (95% CI 
[1.20, 1.75]) as likely to be in the high symptom cluster group compared to participants 
who had survived between 10 to 29 years since cancer diagnosis. Participants who were 
diagnosed with cancer when they were more than 10 years old were 1.35 times (95% CI 
[1.09, 1.68]) as likely to be in the high symptom cluster group compared to participants 
who were diagnosed with cancer at less than four years old.  
Female participants were 1.41 times (95% CI [1.17, 1.71]) as likely to be in the 
high symptom cluster group compared to male participants. White non-Hispanic 
participants were more likely to be in the high cluster group compared to other races 
including Black non-Hispanic and Hispanic participants, but this is not statistically 
significant. However, education level had an effect on symptom cluster membership. 
Those with less education were more likely to be in the high symptom cluster group. For 
example, patients with less than a high school diploma were 3.90 times (95% CI [2.78, 
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5.48]) as likely to be in the high symptom cluster group compared to participants with the 
highest education level (more than college education).  
Participants who were living with a partner, widowed, divorced, separated, or 
single were 1.30 times (95% CI [1.07, 1.58]) more likely to be in the high symptom 
cluster compared to participants who were currently married. Participants who were 
currently unemployed were 3.36 times (95% CI [2.75, 4.10]) more likely to be in the high 
symptom cluster group compared to participants who were currently employed. 
Participants who had difficulty obtaining health insurance were 2.27 times (95% CI 
[1.83, 2.81]) more likely to be in the high symptom cluster group compared to 
participants without difficulty obtaining health insurance.  
Furthermore, lower annual household income was also related to more risk of 
being in the high symptom cluster group. Participants with an annual household income 
of less than $39,999 were 2.48 times (95% CI [1.98, 3.10]) more likely to be in the high 
symptom cluster group compared to participants with an annual household income of 
greater than $80,000. Annual personal income showed a similar risk pattern with the 
annual household incomes. In addition, participants who experienced secondary cancer 
were 1.48 times (95% CI [1.14, 1.92]) more likely to be in the high symptom cluster 
group compared to participants who did not experience secondary cancer.  
B2. Clinical predictors of cluster membership (using bivariate analyses).  
Participants who were diagnosed with a central nervous system tumor (OR: 1.60, 95% CI 
[1.17, 2.20]) and lymphoma (OR: 1.39, 95% CI [1.08, 1.79]) were more likely to be in the 
high symptom cluster group compared to participants who were diagnosed with 
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leukemia. Participants who were treated with any type of chemotherapy were 1.28 times 
(95% CI [1.01, 1.62]) more likely to be in the high symptom cluster group compared to 
participants who were not treated with chemotherapy. 
Regarding each type of chemotherapy, participants who were treated with 
anthracycline were 1.47 times more likely (95% CI [1.21, 1.79]) and those treated with 
alkylating agents were 1.49 times more likely (95% CI [1.25, 1.82]) to be in the high 
symptom cluster group compared to participants who were not treated with either of these 
agents. Participants who were treated with radiotherapy were statistically significantly 
different between the two symptom clusters. For example, patients who were treated with 
radiotherapy were 1.93 times (95% CI [1.58, 2.35]) more likely to be in the high 
symptom cluster group compared to participants who were not treated with radiotherapy. 
Specifically, among types of radiotherapy, participants who were treated with 
radiotherapy in the head or neck area showed the highest likelihood such that they were 
1.91 times more (95% CI [1.57, 2.31]) likely to be in the high symptom cluster group 
compared to participants who were not treated with radiotherapy in the head or neck area. 
Participants who were treated in the chest or lung areas, or pelvis, abdominal, or urinary 
areas each showed 1.7 times greater likelihood of being in the high symptom cluster 
group compared to participants who were not treated in each of the same areas. The 
surgery variable was not statistically significantly different between the two symptom 
clusters.  
Also, the modality of treatment was examined since most types of cancer were 
treated with a combination of treatments including chemotherapy, radiotherapy, and 
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surgery. The modality of treatment was regrouped for this analysis. Participants who 
were treated with only chemotherapy (reference group) were categorized into one group 
that was used as the reference group. Participants who were treated with chemotherapy 
and radiotherapy; chemotherapy and surgery; surgery only; or radiotherapy only were 
categorized into one group (middle group). Participants who were treated with three types 
of treatments including chemotherapy, surgery, and radiotherapy; and surgery and 
radiotherapy were categorized into one group (last group). It is expected that the last 
group has the highest risk of symptoms compared to the reference group that was only 
treated with chemotherapy. As expected, participants in the last group were 2.47 times 
(95% CI [1.74, 3.49]) more likely to be in the highest cluster symptom group compared 
to participants who were treated with chemotherapy alone. Participants in the middle 
group were 1.70 times (95% CI [1.20, 2.41]) more likely to be in the high symptom 
cluster group compared to those who were treated with chemotherapy alone.  
B3. Demographic and clinical predictors of cluster membership (using 
multivariable analysis). Multivariable analyses were conducted using regression 
analysis. The results are presented in Table 5. Several variables were used, including 
participants’ ages at that time of survey, gender, race, educational attainment, marital 
status, employment status, difficulty obtaining health insurance, annual personal income, 
alkylating chemotherapeutic agents, and head/neck area radiotherapy. These variables 
were statistically significantly different between the two symptom clusters. Survivors 
older than 40 years old at the survey had 2.16 times (95% CI [1.41, 3.32]) greater 
likelihood to be in the high symptom cluster group compared to survivors with younger 
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age (between 18 to 29 years old) at the time of the survey. Female patients were 1.37 
times (95% CI [1.08, 1.75]) more likely to be in the high symptom cluster group 
compared to male patients. The ethnicity/race variable was not significant using the 
bivariate analysis, but it was statistically significant using multivariable analysis. For 
example, patients who were non-Hispanic White were 1.55 times (95% CI [1.13, 2.14]) 
more likely to be in the high symptom cluster group compared to other races/ethnicities 
(e.g., non-Hispanic Black and other races).  
Those attaining the lowest level of education were more likely to be in the high 
symptom cluster group (OR: 2.77, 95% CI [1.84, 4.16]) compared to the reference group 
that has more than a college education. Unmarried survivors (e.g., living with partner, 
widowed, divorced, separated, or single) showed 1.50 times (95% CI [1.16, 1.94]) greater 
likelihood of being in the high symptom cluster compared to those currently married. 
Survivors with currently unemployed status were 2.58 times (95% CI [1.97, 3.38]) more 
likely to be in the high symptom cluster group compared to employed survivors. With 
regard to income, survivors who had lower annual personal income (none to ≤ $19,999) 
were 1.76 times (95% CI [1.12, 2.79]) more likely to be in the high symptom cluster 
group compared to survivors with the highest income level (≥ $60,000).  
Regarding chemotherapy, alkylating agents was the only significant factor more 
likely to be found in the high symptom cluster group. For example, survivors who were 
treated with alkylating agents were 1.30 times (95% CI [1.00, 1.69]) more likely to be in 
the high symptom cluster compared to survivors who were not treated with that agent. 
Among types of radiotherapy, survivors who were treated with head or neck radiotherapy 
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were the only statistically significant type. Those receiving head or neck radiotherapy 
were 1.48 times (95% CI [1.12, 1.96]) more likely to be in the high symptom cluster 
compared to those not treated with head or neck radiotherapy.  
 
Table 5 
 
Associations of Symptom Subgroups with Demographics and Clinical Variables  
 
 Bivariate analysis Multivariable analysis 
 High symptom cluster vs. Low symptom cluster 
 OR p 95% CI 
LL       UL  
OR p 95% CI 
LL       UL 
Age at survey        
  18-29 years ref   ref   
  30-39 years 1.48 <.0001 [1.19, 1.83] 2.04 <.0001 [1.49, 2.80] 
  ≥ 40 years  1.92 <.0001 [1.49, 2.48] 2.16 <.0001 [1.41, 3.32] 
Time since cancer diagnosis        
  10-29 years ref   ref   
  ≥ 30 years 1.45 <.0001 [1.20, 1.75] 1.21 .241 [0.88, 1.67] 
Age at cancer diagnosis        
  0-4 years ref      
  5-9 years 1.19 .185 [0.93, 1.53]    
  ≥ 10 years 1.35 <.0001 [1.09, 1.68]    
Sex        
  Male  ref      
  Female 1.41 <.0001 [1.17, 1.71] 1.37 .010 [1.08, 1.75] 
Race/ethnicity       
  White, non-Hispanic 1.23 .105 [0.96, 1.57] 1.55 .007 [1.13, 2.14] 
  Others ref   ref   
Educational background        
  Less than high school 
diploma  
3.90 <.0001 [2.78, 5.48] 2.77 <.0001 [1.84, 4.16] 
  High school graduate/GED  2.16 <.0001 [1.66, 2.82] 1.97 <.0001 [1.42, 2.75] 
  Some college/ training after 
high school 
1.45 .002 [1.15, 1.84] 1.45 <.0001 [1.09, 1.94] 
  More than college education ref      
Marital status        
  Married  ref   ref   
  Living with a partner/ 
widowed/      divorced/ 
separated/single 
1.30 .008 [1.07, 1.58] 1.50 .002 [1.16, 1.94] 
Employment status        
 Currently employed ref      
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 Currently unemployed 3.36 <.0001 [2.75, 4.10] 2.58 <.0001 [1.97, 3.38] 
Had difficulty obtaining    
   health insurance 
      
   No ref      
   Yes 2.27 <.0001 [1.83, 2.81] 2.09 <.0001 [1.62, 2.71] 
Annual household incomes        
  ≤$39,999 2.48 <.0001 [1.98, 3.10]    
  $40,000 to $79,999 0.87 .291 [0.66, 1.13]    
  ≥$80,000 ref      
Annual personal income        
  None to ≤$19,999 2.49 <.0001 [1.81, 3.42] 1.76 .015 [1.12, 2.79] 
  $20,000 to $59,999 1.10 .593 [0.78, 1.55] 1.24 .339 [0.80, 1.92] 
  ≥$60,000 ref   ref   
Second cancer        
  No   ref      
  Yes 1.48 .004 [1.14, 1.92]    
Cancer Diagnosis        
 Leukemia ref      
 Lymphoma     1.39 .010 [1.08, 1.79]       
 Central nervous system tumor  1.60 .004 [1.16, 2.20]    
 Sarcoma 0.78 .035 [0.61, 0.98]    
Chemotherapy        
 Any chemotherapy 1.28 .038 [1.01, 1.62]    
 Corticosteroids 1.13 .213 [0.93, 1.36]    
 Mercaptopurine/Thioguanine 1.07 .481 [0.88, 1.30]    
 Methotrexate 0.96 .674 [0.80, 1.16]    
 Erwinia-/ L-/ Peg-
asparaginase 
0.92 .390 [0.75, 1.12]    
 
Cisplatin/carboplatin/oxaliplati
n 
1.37 .023 [1.05, 1.80] 1.32 .138 [0.92, 1.89] 
 Anthracycline  1.47 <.0001 [1.21, 1.79]    
 Alkylating agents  1.49 <.0001 [1.25, 1.82] 1.30 .050 [1.00, 1.69] 
 Vincristine 1.15 .185 [0.94, 1.41] 1.01 .935 [0.76, 1.36] 
 Other agents  1.04 .647 [0.87, 1.26]    
Radiotherapy       
 Any radiotherapy  1.93 <.0001 [1.58, 2.35]    
 Head/neck area  1.91 <.0001 [1.57, 2.31] 1.48 .006 [1.12, 1.96] 
 Chest/lung area 1.67 <.0001 [1.42, 1.96] 1.96 .297 [0.77, 2.31] 
 Pelvis/abdominal/urinary area 1.69 <.0001 [1.39, 2.06] 0.80 .476 [0.43, 1.48] 
 Reproductive area  1.50 <.0001 [1.21, 1.87] 1.02 .930 [0.67, 1.54] 
 Muscle area 1.57 <.0001 [1.30, 1.90] 1.18 .669 [0.55, 2.50] 
 Invasive surgery 1.18 .126  [0.96, 1.45] 1.32 .067 [0.98, 1.78] 
Types of treatments        
 Chemotherapy alone ref      
 Chemotherapy + 
Radiotherapy;  
1.70 
 
.003 [1.20, 2.41]    
  
86 
 
   Chemotherapy + Surgery;  
   Surgery only; Radiotherapy 
only;  
Chemotherapy + Surgery+         
Radiotherapy; Surgery + 
Radiotherapy 
2.47 
 
<.0001 
 
[1.74, 3.49]    
Note. Leukemia includes (Acute lymphoblastic leukemia, acute myeloid leukemia, & other 
leukemia); Lymphoma includes (Hodgkin’s lymphoma & non-Hodgkin’s lymphoma); Sarcoma 
includes (Ewing’s Sarcoma, osteosarcoma, rhabdomyosarcoma, neuroblastoma Wilms’ tumor, & 
bone tumors); OR=Odds ratio; CI=confidence interval; LL=low limit, UL=upper limit; 
ref=reference.         
 
 
  Hypothesis C.   
  It was hypothesized that cluster membership would be associated with more 
negative distal outcomes such that those in the high symptom group would show lower 
physical and mental functioning. This hypothesis was supported. Table 6 represents this 
result. Those in the high symptom cluster group reported a lower physical component 
summary score (M = 40.19, SE = 0.40) and a lower mental component summary score 
(M = 36.09, SE = 0.46) compared to the HRQOL scores of the low symptom cluster 
group.  
 
Table 6  
 
Difference in HRQOL for Each Class in Survivors of Childhood Cancers 
 
 High symptom cluster 
(n = 888, 28.4%) 
Low symptom cluster 
(n = 2241, 71.6%) 
 
 M (SD) 
 
M (SD) χ2 p 
Physical 
Component 
Summary 
40.19 (0.40) 54.98 (0.16) 1181.11 <.0001 
 
Mental 
Component 
Summary 
36.09 (0.46) 53.08 (0.21) 1070.90 <.0001 
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C1. Demographic, clinical predictors, and physical HRQOL. Multivariable 
logistic analyses were conducted to examine the relationships between demographics, 
treatment variables, and HRQOL. HRQOL includes a physical component summary 
(PCS) and a mental component summary (MCS) score. Table 7 and Table 8 summarize 
the analysis results. Age at time of survey, educational background, employment status, 
having difficulty obtaining health insurance, annual personal income, two types of 
chemotherapy, and one type of radiotherapy showed statistically significant effects on 
PCS. Specifically, for a unit of change of age in survivors older than 40 at survey 
(compared to survivors from 18 to 29 years old at the time of survey), the PCS changed 
by -4.80 (95% CI [-6.11, -3.49], holding all other variables constant. Regarding 
education, for a unit of change of education in survivors with less than a high school 
diploma compared to survivors with more than a college education, PCS changed by -
3.19 (95% CI [-4.64, -1.74]), holding all other variables constant. For a unit of change of 
unemployment status, the PCS changed by -2.39 (95% CI [-3.25, -1.53]), holding all 
other variables constant. For one unit of change of annual personal income from none to 
≤ 19,999 compared to annual personal income ≥ $60,000, PCS changed by -1.77 (95% CI 
[-2.91, -0.63]), holding all other variables constant. With regard to chemotherapy, with 
one unit of change of using platinum chemotherapy (cisplatin/carboplatin/oxaplatin), the 
PCS changed by -1.51 (95% CI [-2.57, -0.45]), holding all other variables constant. 
Regarding radiotherapy, one unit of change of radiotherapy treatment in the muscle, the 
PCS changed by -2.39 (95% CI [-4.47, -0.31]), holding all other variables constant.  
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Table 7  
 
Multivariable Associations of Demographic and Clinical Variables with PCS 
 
 PCS  β SE  p 95% CI 
LL         UL 
Age at survey      
 18-29 years ref    
 30-39 years -2.18 0.45 <.0001 [-3.06, -1.30] 
 ≥ 40 years  -4.80 0.67 <.0001 [-6.11, -3.49] 
Time since cancer diagnosis      
 10-29 years ref    
 ≥ 30 years -0.74 0.46 .107 [-1.64, 0.16] 
Sex      
  Male  ref    
  Female -0.29 0.34 .391 [-0.96, 0.38] 
Race/ethnicity      
  White, non-Hispanic 0.10 0.42 .807 [-0.72, 0.92] 
  Other  ref    
Educational background      
  Less than high school diploma  -3.19 0.74 <.0001 [-4.64, -1.74] 
  High school graduate/ GED  -1.19 0.50 .018 [-2.17, -0.21] 
  Some college/ training after high 
school 
-0.54 0.40 .172 [-1.32, 0.24] 
  More than college education ref    
Marital status      
  Married  ref    
 Living with a partner/widowed/       
divorced/ separated/single 
0.43 0.36 .237 [-0.28, 1.14] 
Employment status      
 Currently employed ref    
 Currently unemployed -2.39 0.44 <.0001 [-3.25, -1.53] 
Had difficulty obtaining health 
insurance 
    
   No ref    
   Yes -1.48 0.42 <.0001 [-2.30, -0.66] 
Annual personal income      
 None to ≤$19,999 -1.77 0.58 .002 [-2.91, -0.63] 
 $20,000 to $59,999 -0.92 0.49 .060 [-1.88, 0.04] 
 ≥$60,000 ref    
Chemotherapy      
 Cisplatin/carboplatin/oxaliplatin -1.51 0.54 .005 [-2.57, -0.45] 
     
 Alkylating agents  -0.71 0.36 .047 [-1.42, 0.00] 
 Vincristine 0.60 0.40 .134 [-0.18, 1.38] 
Radiotherapy     
  Head/neck area  0.03 0.39 .946 [-0.73, 0.79] 
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  Chest/lung area 1.51 0.77 .052 [0.00, 3.02] 
  Pelvis/abdominal/urinary area -0.51 0.96 .598 [-2.39, 1.37] 
  Reproductive area  0.29 0.60 .634 [-0.89, 1.47] 
  Muscle area -2.39 1.06 .025 [-4.47, -0.31] 
 Invasive surgery -0.43 0.38 .256 [-1.17, 0.31] 
Note. Leukemia includes (Acute lymphoblastic leukemia, acute myeloid leukemia, & other 
leukemia); Lymphoma includes (Hodgkin’s lymphoma & non-Hodgkin’s lymphoma); Sarcoma 
includes (Ewing’s Sarcoma, osteosarcoma, rhabdomyosarcoma, neuroblastoma Wilms’ tumor, & 
bone tumors); CI=confidence interval; LL=low limit, UL=upper limit; ref=reference.  
 
 
C2. Demographic, clinical predictors, and mental HRQOL. Several variables 
showed statistically significant effects on the MCS in several categories including sex, 
education, marital status, employment status, difficulty obtaining health insurance, and 
two kinds of chemotherapies. Table 8 presents these results. For females, the MCS 
changed by -1.69 (95% CI [-2.47, -0.91]), holding all variables constant.  For one unit 
change of education, the MCS changed by -1.91 (95% CI [-3.60, -0.22]), holding all 
variables constant. Interestingly, some types of chemotherapy showed positive effects on 
better mental health. For example, for one unit change of treatment with platinum drugs 
(cisplatin/carboplatin/oxaliplatin), the MCS changed by 1.60 (95% CI [0.33, 2.87]), 
holding all variables constant. For one unit change of treatment with alkylating agents, 
the MCS changed by 1.07 (95% CI [0.23, 1.91]), holding all variables constant. In a 
multivariable analysis, there were no significant effects between radiation therapy and 
MCS.  
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Table 8  
 
Multivariable Associations of Demographic and Clinical Variables with MCS 
 
MCS  
 
β SE  p 95% CI 
LL         UL 
Age at survey      
 18-29 years ref    
 30-39 years -0.23 0.51 .655 [-1.23, 0.77] 
 ≥ 40 years  0.73 0.73 .321 [-0.70, 2.16] 
Time since cancer diagnosis      
 10-29 years ref    
 ≥ 30 years 0.23 0.51 .655 [-0.77, 1.23] 
Sex      
  Male  ref    
  Female -1.69 0.40 <.0001 [-2.47, -0.91] 
Race/ethnicity      
  White, non-Hispanic -0.27 0.51 .594 [-1.27, 0.73] 
  Other  ref    
Educational background      
  Less than high school diploma  -1.91 0.86 .026 [-3.60, -0.22] 
  High school graduate/ GED  0.48 0.57 .403 [-0.64, 1.60] 
  Some college/ training after high 
school 
0.16 0.46 .725 [-0.74, 1.06] 
  More than college education ref    
Marital status      
  Married  ref    
  Living with a partner/ widowed/  
divorced/ separated/single 
-1.09 0.43 .011 [-1.93, -0.25] 
Employment status      
 Currently employed ref    
 Currently unemployed -1.73 0.52 .001 [-2.75, -0.71] 
Had difficulty obtaining health 
insurance 
    
 yes ref    
 no -1.02 0.48 .034 [-1.96, -0.08] 
Annual personal income      
 None to ≤$19,999 -0.43 0.66 .519 [-1.72, 0.86] 
 $20,000 to $59,999 -0.71 0.53 .180 [-1.75, 0.33] 
 ≥$60,000 ref    
Chemotherapy      
Cisplatin/carboplatin/oxaliplatin 1.60 0.65 .014 [0.33, 2.87] 
 Alkylating agents  1.07 0.43 .012 [0.23, 1.91] 
 Vincristine -0.60 0.48 .214 [-1.54, 0.34] 
Radiotherapy     
  Head/neck area  0.44 0.45 .325 [-0.44, 1.32] 
  Chest/lung area 1.01 0.93 .282 [-0.81, 2.83] 
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  Pelvis/abdominal/urinary area -0.21 1.13 .852 [-2.42, 2.00] 
  Reproductive area  -0.56 0.69 .416 [-1.91, 0.79] 
  Muscle area 0.51 1.28 .693 [-2.00, 3.02] 
Invasive surgery -0.32 0.47 .495 [-1.24, 0.60] 
Note. Leukemia includes (Acute lymphoblastic leukemia, acute myeloid leukemia, & other 
leukemia); Lymphoma includes (Hodgkin’s lymphoma & non-Hodgkin’s lymphoma); Sarcoma 
includes (Ewing’s Sarcoma, osteosarcoma, rhabdomyosarcoma, neuroblastoma Wilms’ tumor, & 
bone tumors); CI=confidence interval; LL=low limit, UL=upper limit; ref=reference.  
 
 
 Hypothesis D.   
 
During the data analysis, the comprehensive relationships among predictors, 
symptom clusters, and HRQOL were examined. In particular, the moderating effect of 
the symptom clusters between predictors and quality of life were tested. These 
relationships were tested in order to more comprehensively understand the relationships 
between predictors, symptom clusters, and HRQOL among these survivors. Four 
common variables were found that demonstrated a statistically significant effect on both 
PCS and MCS. These variables included educational background (less than a high school 
diploma), difficulty obtaining health insurance, employment status, and two types of 
chemotherapy (cisplatin/carboplatin/oxaliplatin and alkylating agents). The Wald test was 
used to examine the moderating effects of symptom cluster membership on the 
relationship between these four predictors and both physical HRQOL and mental 
HRQOL using Mplus. The “omnibus” Wald test (in which all moderating effects were 
tested) was significant overall. Following this significant omnibus Wald test, individual 
tests were performed for each relationship. Table 9 presents the relationship between 
predictors and HRQOL in each symptom cluster. For example, for individuals in the high 
symptom cluster group who had less than a high school diploma, their educational level 
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had a stronger negative relationship with better physical HRQOL compared to 
individuals in the low symptom cluster group, whereas this educational level had a 
significant effect on mental HRQOL only in the high symptom clusters group. Regarding 
chemotherapy, use of alkylating agents had a significantly stronger impact on physical 
HRQOL for those in the high symptom cluster group compared to those in the low 
symptom cluster group. However, the alkylating agents had a significant effect on mental 
HRQOL only for those in the low symptom cluster group; the estimator was less than 1.0.  
 
Table 9 
 
Omnibus Wald Test Results of Coefficient Equality of Predictors on PCS and MCS  
 
 High symptom cluster Low symptom cluster 
 
PCS  β SE  p 95% CI 
LL         UL  
β SE  p 95% CI 
LL         UL 
Education         
≤ High school  -2.79 
 
1.03 .007 [-4.81, -0.77] -1.59 0.67 .017 [-2.90, -0.28] 
 ≥ College  
 
ref        
Had difficulty 
obtaining health 
insurance 
        
  No ref        
  Yes 
 
-2.92 0.81 .0001 [-4.51, -1.33] -0.93 0.36 .011 [-1.64, -0.22] 
Employment          
 Currently 
employed 
ref        
Currently 
unemployed 
 
-5.33 0.81 .0001 [-6.92, -3.74] -0.23 0.34 .497 [-0.90, 0.44] 
Chemotherapy          
Cisplatin/carbop
latin/oxaliplatin 
-0.25 1.01 .802 [-2.23, 1.73] -0.99 0.49 .042 [-1.95, -0.03] 
Alkylating 
agents 
 
-1.93 0.81 .017 [-3.52, -0.34] -0.55 0.25 .029 [-1.04, -0.06] 
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MCS  β SE  p 95% CI 
LL         UL  
β SE  p 95% CI 
LL         UL 
Education         
≤ High  school  -3.01 1.44 .037 [-5.83, -0.19] -0.49 0.83 .557 [-2.12, 1.14] 
  ≥ College  
 
ref        
Had difficulty 
obtaining health 
insurance 
        
  No ref        
  Yes -1.38 0.94 .144 [-3.22, 0.46] -1.29 0.39 .001 [-2.05, -0.53] 
Employment          
 Currently 
employed 
ref        
 Currently  
unemployed 
-2.54 0.94 .007 [-4.38, -0.70] -0.97 0.41 .018 [0.17, 1.77] 
 
Chemotherapy  
        
Cisplatin/carbop
latin/oxaliplatin 
3.78 1.29 .003 [1.25, 6.31] 0.66 0.55 .227 [-0.42, 1.74] 
 Alkylating 
agents 
1.77 0.98 .070 [-0.15, 3.69] 0.77 0.33 .022 [0.12, 1.42] 
Note. CI=confidence interval; LL=low limit, UL=upper limit; ref=reference.  
 
Summary of Results 
The objective of this chapter was to report the results related to the research 
questions and hypotheses in the current study. A substantial sample (n = 3,129) was used 
for these analyses. A person-centered approach, Vermunt’s three-step approach, was 
employed using Mplus software. All of the hypotheses were supported. The first 
hypothesis stated that there would be subgroup membership of survivors who shared 
common profiles across multiple symptoms associated with their childhood cancer and its 
treatments. This hypothesis was supported in that two different groups were identified: 
the high symptom cluster and low symptom cluster.  
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The second hypothesis stated that demographic and clinical variables would 
differentially predict subgroup membership. This second hypothesis was supported. 
Except for a few variables, most of the variables predicted subgroup membership of the 
symptom cluster. For example, survivors with lower education status, lower income, 
those who were unemployed, those of older age at the time of the survey (more than 40 
years old), those with a longer time since the cancer diagnosis, and females were more 
likely to be in the high symptom cluster group. Regarding clinical variables, survivors 
with older age at cancer diagnosis (more than 10 years old), those who had experienced 
secondary cancer, were diagnosed with lymphoma or central nervous system tumors 
cancers, those treated with any type of chemotherapy, those treated with any 
radiotherapy, and those treated with a combination of therapies (chemotherapy, 
radiotherapy, and surgery) were more likely to be in the high symptom cluster group.  
The third hypothesis stated that survivors who belonged to the high physical and 
psychological symptoms subgroups would have poorer HRQOL. This hypothesis was 
supported. Survivors who belonged to the high symptom cluster group showed lower 
physical summary and mental summary scores compared to survivors who belonged to 
the low symptom cluster group.  
The fourth hypothesis stated that there would be mediating effects of symptom 
subgroup membership between demographic variables, clinical predictors and HRQOL. 
This hypothesis was supported. The results of this chapter will be discussed in the next 
chapter, including comparison of findings with other research findings, limitations of the 
current study, implications for clinicians, and recommendations for future study.
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CHAPTER V  
DISCUSSION 
The purpose of this study was to identify subgroup membership among survivors 
of childhood cancer and to find factors related to HRQOL status. Chapter V provides an 
interpretation of the findings related to the four hypotheses. The Dynamic Symptoms 
Model was used as the theoretical framework to identify the relationship between 
sociodemographic variables, symptom clusters, and patient outcomes. Using mixture 
modeling, two symptom clusters were identified as a best-fitting model, and various 
sociodemographic and clinical factors related to symptom clusters and HRQOL were 
examined. Major findings about the relationships between predictors and each symptom 
cluster, and between predictors and HRQOL, were also examined. In addition, eight 
different types of chemotherapy and five different body areas of radiotherapy and their 
relationship with HRQOL were tested. In this chapter, these findings are compared and 
contrasted with prior research on symptom clusters in adult survivors of cancer and 
childhood cancer. Clinical, research, and nursing implications are presented and 
limitations for this study are discussed. Finally, future research recommendations are also 
addressed.  
Few studies have examined symptom clusters and HRQOL among survivors of 
childhood cancer. The few studies that have been conducted included less than 150 
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participants (Hockenberry et al., 2011; Yeh et al., 2008). These prior studies examined 
sociodemographic and clinical factors in the context of symptom clusters. The current 
study included 3,129 participants. In the current project, detailed treatment information 
was examined, including several types of chemotherapy and radiotherapy of various body 
parts, in order to explore their relationships to symptom clusters and HRQOL among the 
childhood cancer survivors.  
Overall, findings from this study suggest that participants who were older when 
they took the survey, those for whom more time has passed since their cancer diagnosis, 
were female, had a lower educational level, were unmarried, unemployed, and had lower 
incomes were more likely to be in the high symptom cluster group. In addition, 
participants who had experienced secondary cancer, had been diagnosed with CNS 
tumors or lymphoma, or had been treated with chemotherapy or radiotherapy were more 
likely to be in the high symptom cluster group. In this current study, the symptom 
clusters based on symptom levels were related to quality of life of survivors. For 
example, survivors who were in the low symptom cluster reported better physical 
HRQOL and mental HRQOL than survivors who were in the high symptom cluster 
group.  
Several sociodemographic factors and clinical factors were found to be related to 
poorer HRQOL among survivors. Those who were older when they took the survey, had 
less than a high school diploma, were unemployed at the time of the survey, had a lower 
annual personal income (less than $19,999), and were treated with either chemotherapy 
or muscle radiotherapy were more likely to report poorer physical HRQOL. Survivors 
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who were female, had less than a high school diploma, answered “other” to the marital 
status questions (i.e., living with partner, widowed, divorced, separated, or single), were 
unemployed at the time of the survey, and had difficulty obtaining health insurance were 
more likely to report poorer mental HRQOL. However, being treated with certain 
chemotherapy (i.e., cisplatin/carboplatin/oxaliplatin, or alkylating agents) was associated 
with better mental health. Detailed information about predictors of symptom clusters and 
the relationship between predictors, symptom clusters, and HRQOL are reported below 
and compared with the findings from other studies.   
Participant Demographics 
There were 3,129 study participants who were treated for their cancer at St. Jude 
Children’s Research Hospital and subsequently surveyed through the St. Jude Life Cohort 
Study (SJLIFE), included in this study. The study participants were nearly evenly 
distributed between the genders. Other studies on survivors of childhood cancer have 
reported similar rates of participation by both genders (Ameringer, Erickson, 
Macpherson, Stegenga, & Linder, 2015). In the current study, most participants were 
non-Hispanic White, 13 % were non-Hispanic Black, and nearly 5% were Hispanic. 
Ameringer’s study included 72 participants with adolescent and young adult cancer: 79% 
non-Hispanic White and 10% non-Hispanic Black. Using the Childhood Cancer Survivor 
Study (CCSS) data, Nolan et al. studied HRQOL among survivors of adolescent cancer. 
With 2,064 cancer survivors participating, 92% were non-Hispanic White (Nolan et al., 
2014). This race/ethnicity breakdown is similar to the current study.  
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In the current study, the majority of participants had obtained more than a high 
school diploma; more than one-third of the participants had a college degree or higher. 
These reported education levels are similar to other studies. Among 425 survivors of 
childhood cancer in Switzerland, more than 90% had obtained more than secondary 
education (Wengenroth et al., 2015). In a report using the CCSS data, 44% of participants 
had a college degree (Nolan et al., 2014). In another study of 170 survivors of childhood 
cancer, 73% had at least some college education (Badr et al., 2013).  
In this study, half of the participants were married. In a different study, 25% (n = 
7) of survivors of bone tumors were married (Barrera, Teall, Barr, Silva, & Greenberg, 
2012). However, the mean age of those participants was 24 years, which is younger than 
the mean age of participants in the study reported here. Employed participants accounted 
for 66.8% of the sample at the time of the survey and they reported working full-time or 
part-time. This percentage is higher than Badr et al.’s study, which found that 52% of 
participants were employed (Badr et al., 2013). In the current study, most participants had 
insurance and had no difficulty obtaining health insurance. Twelve percent of participants 
had no personal income annually, and 40% of participants had incomes of less than 
$19,999 per year. Participants who earned between $20,000 and $59,999 per year made 
up 36% of the sample.  
Leukemia and sarcoma were the most prevalent types of cancer reported, with 
lymphoma (20.2%) the next most prevalent. Central nervous system tumors accounted 
for less than 10% of reported cancers. In one study in Switzerland, leukemia was the 
most common cancer among children, and CNS tumor and lymphoma were each 8% 
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(n=32) (Wengenroth et al., 2015). The rate of survivors who reported CNS tumors in that 
study is similar to the current study, but lymphoma was less prevalent in the current 
study. If all of their categories including neuroblastoma, renal tumor, bone tumor, soft 
tissue sarcoma are categorized into a general sarcoma category (as in the current study), 
then the rate of sarcoma is similar between the two studies. In another study, Ameringer 
et al. included participants of older age at cancer diagnosis (mean 18.5 years), and 
leukemia and lymphoma were the most prevalent types of cancer in this age group 
(respectively 20% and 30%) (Ameringer et al., 2015). In the current study, fifteen percent 
of participants reported experiencing secondary cancer. Childhood cancer survivors who 
reported a relapse experience accounted for approximately 11% in other studies (Hsiao et 
al., 2017; Wengenroth et al., 2015).  
In the current study, the majority of participants (77%) were treated with 
chemotherapy, and 60% of participants were treated with radiotherapy. In Wengenroth et 
al.’s study, most survivors received chemotherapy (81%, n = 344), more than half 
received surgery (59%, n = 252), and less than 20% had radiotherapy (17%, n = 74) 
(Wengenroth et al., 2015). The difference between the studies in percentage of 
participants receiving radiotherapy treatment might be related to the treatment era or type 
of cancer. For example, Wengenroth’s participants were diagnosed between 1976 and 
2005, and participants in the current study were diagnosed with cancer between 1962 and 
2002. Radiation therapy is an essential treatment for childhood cancer survivors, but it 
can bring long-term complications. Physical body and tissues are still growing in children 
and adolescents, so tissues or organs can be sensitive to radiotherapy. The complications 
  
100 
 
or late effects from radiotherapy are associated with the treated organs, type of radiation 
administered, daily treatment, accumulated dose, and age at the time of treatment 
(Oeffinger & Hudson, 2004). It has been known that complications of brain radiotherapy 
are a decrease in cognitive function. In order to decrease complications, reduced dosages 
have been used with similar efficacy (Oeffinger & Hudson, 2004). Armstrong and 
colleagues studied long-term effects of radiation exposure using nearly 14,000 survivors 
from the childhood cancer survivor study (CCSS) data. They found that survivors who 
were treated with radiotherapy have an increased risk of late mortality (defined as death 
occurring 5 years after their cancer diagnosis), secondary cancer, obesity, pulmonary and 
cardiac dysfunction, and chronic conditions (Armstrong et al., 2010). In the current study 
there were more types of lymphoma and sarcoma that might have necessitated 
radiotherapy. Half of the participants were treated with head/neck radiotherapy. In 
addition, 70% of participants had invasive surgery that was related to their cancer or 
treatment within five years of their cancer diagnosis.  
Discussion of Hypotheses 
Hypothesis A.    
 Hypothesis A was supported in that two meaningful subgroups of survivors with 
heterogeneous symptom patterns were identified. Several risk factors were associated 
with the long-term complications of childhood cancer including type of cancer, age at the 
time of treatment, and whether or not they were receiving chemotherapy and radiation 
therapy (Oeffinger, Hudson, & Landier, 2009). Individuals were clustered based on their 
symptom patterns. Two distinctive subgroups were found that represent different patterns 
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of symptom clusters in survivors of childhood cancer. Survivors who are in the high 
symptom cluster reported high scores for both physical and psychological symptoms, and 
survivors in the low symptom group reported low scores for both sets of symptoms. 
These groups were named the high symptom cluster and the low symptom cluster.  
 Other studies of symptom clusters among adults with cancer have identified a 
similar number of clusters, usually between three and five. In addition, researchers have 
named clusters based on the unique symptoms of each cluster. For example, Kim and 
colleagues defined five symptom clusters using a longitudinal design. These five groups 
were the “constantly low symptom subgroup”; “gradually increasing symptom 
subgroup”; “start low with dramatic increase and decrease patterns subgroup”; 
“constantly high pattern subgroup”; and the “start high with dramatic increase and 
decrease pattern subgroup” (Kim et al., 2014). Also, Miaskowski and colleagues 
identified four symptom clusters based on patients’ experiences with four highly 
prevalent symptoms (Miaskowski et al., 2006). Their four subgroups were high fatigue 
and low pain; all low symptoms (i.e., low fatigue and low pain); low fatigue and high 
pain; and all high symptoms (i.e., high fatigue and high pain). Yeh and colleagues 
identified five symptom clusters using a variable-centered approach in older Taiwanese 
children with cancer (Yeh et al., 2008). Their five symptom clusters were symptoms of 
sensory discomfort and body image; circulatory and respiratory system malfunction; 
fatigue, sleep disturbance, and depression; body image and eating difficulties; and 
gastrointestinal irritations and pain. Thus, researchers have identified several subgroups 
based on characteristics of each symptom cluster in survivors of cancer patients.  
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 Hypothesis B.  
 Hypothesis B was supported in that demographic or clinical factors differentially 
predicted subgroup membership. The two groups are associated with different 
sociodemographic characteristics and clinical factors. Survivors who belong to the high 
symptom cluster group were older in age (i.e., more than 40 years old at the time of the 
survey); were older at the time of cancer diagnosis (i.e., more than 10 years old); were 
female; and had a lower level of educational attainment (i.e., less than a high school 
diploma). In addition, these groups included survivors who had a marital status other than 
married, such as divorced, single, widowed, or live with partner. Survivors who had no 
job, had difficulty obtaining health insurance, had a lower annual personal income of less 
than $19,999, and who had experienced secondary cancer were more likely to be in the 
high symptom cluster group.  
Sociodemographic factors. In the current study, most variables (including sex, 
education, marital status, employment status, insurance status, annual personal income, 
annual household income, cancer diagnosis, secondary cancer, whether or not received 
and type of chemotherapy, and whether or not received and type of radiotherapy) were 
statistically significantly different between the high symptom cluster and the low 
symptom cluster. The variables of race, age at interview, age at cancer diagnosis, and 
experience with surgery were not different between the clusters. There are few studies 
that examine symptom clusters in survivors of childhood cancer (Ameringer et al., 2015; 
Erickson et al., 2013; Hockenberry et al., 2010, 2011; Yeh et al., 2008), so the current 
study’s findings were also compared with studies of adults with cancer. As mentioned in 
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Chapter II, studies examining the potential for symptom clusters among cancer survivors 
began less than two decades ago, these have primarily been among those with adult 
cancers, and only a few studies have examined associations between experiencing 
symptoms and patient outcomes including functioning and quality of life (Barsevick et 
al., 2006b; Dodd et al., 2001a; Miaskowski et al., 2006).  
Among demographic and clinical factors, employment was the only significant 
factor among four cluster symptom groups in breast cancer patients (Dodd et al., 2010). 
In particular, as might be expected, employed participants belonged to the low symptom 
cluster group rather than the moderate or high symptom cluster group (Dodd et al., 2010). 
A study examining symptom clusters in adult breast cancer patients showed that race was 
not statistically significantly different in the two subgroups (Kim et al., 2012), which was 
similar to the results in the current study. In Kim and Beck’s study, marital status, 
employment status, and symptom management were not significantly different among 
subgroups prior to chemotherapy and/or radiation treatment or within a month after 
treatment. However, the differences in these variables are statistically significant among 
subgroups in the current study. This may be because of the time passed since treatments. 
The current study has long-term survivors’ data regarding symptoms, but Kim and 
colleagues had short-term data regarding symptoms immediately following cancer 
treatment. Symptom frequencies or levels in cancer patients who have recently completed 
their treatments might be different from those who are long-term survivors and who are 
many years beyond their treatments.  
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Clinical factors. Survivors who were diagnosed with lymphoma or a central 
nervous system tumor belonged to the high symptom cluster group. Oeffinger and 
colleagues’ study supports that survivors who were treated for a central nervous system 
tumor and Hodgkin’s lymphoma were considered as belonging to a high-risk group 
experiencing more late effects (Oeffinger et al., 2009). In the current study, survivors 
who were treated with either chemotherapy or radiotherapy were more likely to be in the 
high symptom cluster group. Invasive surgery was not associated with either symptom 
cluster group. Specifically, survivors who were treated with two different categories of 
chemotherapy including “cisplatin/carboplatin/oxaliplatin” and “alkylating” agents were 
more likely to be in the high symptom cluster group. Use of chemotherapy including 
bleomycin, busulfan, and cyclophosphamide have been shown to be related to pulmonary 
fibrosis (Kaplan et al., 1996; O’Driscoll et al., 1990), arguably resulting in symptoms that 
might be associated with those in the high symptom cluster in the current study. 
Similarly, in Armstrong et al. (2010)’s study, being given certain types of chemotherapy 
including cyclophosphamide, bleomycin, busulfan, carmustine, and lomustine was 
associated with increased pulmonary complications. These pulmonary complications 
could persist up to 25 years after cancer diagnosis (Armstrong et al., 2010). Also, use of 
anthracycline chemotherapy and radiotherapy are associated with cardiotoxicity (Adams 
& Lipshultz, 2005). Cardiac toxicity is a major cause of morbidity and mortality in 
survivors of childhood cancer. These serious symptoms likely would have resulted in 
high symptom cluster membership.  
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In the current study, most body areas of radiotherapy were associated with the 
high symptom cluster group. In particular, survivors who were treated with head or neck 
radiotherapy were most likely to be in the high symptom cluster compared to those 
receiving other body areas of radiotherapy. Survivors who were treated with radiotherapy 
may have late effects immediately after treatment or experience them many years later 
(K, C. Oeffinger et al., 2009). For example, survivors who were treated with radiotherapy 
showed three times greater likelihood of developing medical conditions and an eightfold 
increase in the likelihood of having severe health conditions (Armstrong et al., 2010). In 
a study that examined long-term effects of radiation exposures in childhood cancer 
survivors using CCSS data, survivors who were treated with radiotherapy showed late 
mortality, increased risk of developing secondary cancer, pulmonary, cardiac, and thyroid 
dysfunction, as well as increased risks for chronic health conditions (Armstrong et al., 
2010). Use of radiotherapy is associated with long-term pulmonary toxicity and is 
consistent with membership in the high symptom cluster.  
In the current study, the average time since cancer diagnosis was 23 years. 
Among the various body areas of radiotherapy reported by participants, head/neck and 
chest/lung radiotherapy were included in the analyses since a higher percentage of 
participants were treated in these areas of radiotherapy than in other body areas. The 
higher prevalence of brain radiotherapy is due to the fact that brain radiation is used to 
treat survivors who have a brain tumor, acute lymphoblastic leukemia, had and neck soft 
tissue sarcoma, and retinoblastoma in the head or neck (Oeffinger & Hudson, 2004; 
Reimers et al., 2003). Patients who were treated with brain radiation can develop 
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cognitive dysfunction. In particular, survivors who were treated with high dose brain 
radiotherapy showed a decrease in cognitive function. This decreased function was 
related to cancer survivors being less likely to graduate from high school, to gain 
employment, and to live independently from their parents (Reimers et al., 2003).  
In the current study, one fourth of the long-term survivors experienced a 
memory/learning problem. This might be related to the treatment of brain radiotherapy. 
However, the percentage of participants in this study who had obtained a high school 
diploma was 90%, better than the U. S public high school graduation rate (83%) in the 
2014-2015 academic year (National Center for Education Statistics, 2017). In the current 
study, one-third of participants were unemployed, lower than the 4.3% U. S 
unemployment rate in 2017 (United States Department of Labor, 2017). Some of these 
findings may be consistent with Reimers et al.’s (2003) findings that the effects of brain 
radiotherapy in brain tumor survivors were associated with cognitive function decrease. 
However, more research in this area is needed to better understand the unique effects of 
brain radiotherapy and the association with patients’ outcomes.   
In the current study, survivors who were treated with chest or lung radiotherapy 
were more likely to be in the high symptom cluster group. In another study, female 
childhood cancer patients who were treated with chest radiotherapy showed a 10-20% 
prevalence of breast cancer when they became young adults, older than 30 years (Kenney 
et al., 2004; Taylor, Winter, Stiller, Murphy, & Hawkins, 2007). Moreover, chest 
radiotherapy has also been associated with cardiovascular problems. For example, twenty 
years after radiotherapy in the chest area, 16% of survivors of Hodgkin’s lymphoma 
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(median age: 25 years old) reported cardiovascular diseases (Hull, Morris, Pepine, & 
Mendenhall, 2003). The rate of lymphoma diagnosis was 20% and the rate of chest/lung 
radiotherapy was nearly 30% in the current study. Also, the percentage of participants 
who experienced secondary cancer was nearly 15%. So, the participants in the current 
study who were diagnosed with lymphoma might be at a higher risk of having 
cardiovascular problems and/or secondary cancer.  
The relationships between a combination of therapies and symptom clusters were 
examined in the current study. Survivors who were treated with a combination of 
therapies (chemotherapy, surgery, and radiotherapy; surgery only; radiotherapy only) 
were more likely to be in the high symptom cluster group compared to survivors who 
were treated with only chemotherapy. This finding corresponds with common knowledge 
(of pediatric cancer treatment teams) that combination therapies or complex treatments 
may be associated with more (worse) symptoms and poorer functioning. Hsiao et al.’s 
study involved 201 participants of childhood cancer who had survived an average of six 
years since their cancer diagnosis. Among them, survivors who were receiving radiation 
therapy reported higher rates of late effects compared to those who did not receive 
radiation therapy (Hsiao et al., 2017). In Hsiao et al.’s study, the most prevalent 
symptoms were altered body image (31.5%), fatigue (14.9%), and memory/learning 
problems (12.5%). The current study includes long-term survivors of childhood cancer 
(such as 28 years after cancer diagnosis), and the most prevalent symptoms reported by 
participants were pain, disfigurement, and sensation abnormalities. In the current study, 
55% of participants reported altered body image, which is higher than the 31.5% from 
  
108 
 
Hsiao’s study. These findings provide support for the presence of the long-term nature of 
late effects in survivors of childhood cancer. One fourth of participants in the current 
study reported a memory/learning problem, which is higher than that of Hsiao’s study. In 
this study, CNS tumor survivors reported more symptoms; this is similar to Hsiao’s study 
results.  
Using data from childhood cancer survivors (CCSS), 67% (n = 1,309) of 
survivors of adolescent cancer reported disfigurement (Nolan et al., 2014).  This is higher 
than the current study, possibly because Nolan and colleagues included participants who 
were diagnosed with cancer only during adolescence, a developmental time when a focus 
on the body is great (Nolan et al., 2014). Long-term young adult survivors who were 
diagnosed with a brain tumor in childhood experienced late effects including 
ocular/visual impairment, seizure, and mobility disturbances of limb(s). Those 
neurological late effects were associated with poorer physical HRQOL (Blaauwbroek et 
al., 2007; Sato et al., 2014). Many survivors who were in the high symptom subgroup in 
the current study experienced somatization. Similarly, in the low symptom cluster group, 
pain symptoms, disfigurement and memory problems were higher than the other 
symptoms examined. Less than 5% of survivors in this group reported psychological 
symptoms, which is a lower prevalence compared to those in the high symptom cluster 
group.  
Landier and colleagues (2012) reviewed literature to examine the prevalence of 
both late effects and screening tests of these effects (Landier et al., 2012). As a result, 
Landier and colleagues grouped symptoms into three categories based on the levels of 
  
109 
 
symptoms including high, intermediate, and low prevalence. Pulmonary dysfunction 
belonged to the high prevalence symptom group, and the prevalence of pulmonary 
dysfunction in this group was between 13% and 87% from the reviewed studies (Landier 
et al., 2012). In the current study, the prevalence of pulmonary symptoms was lower than 
in Landier’s study. However, pulmonary complications are consistently noted as one of 
the common late effects in long-term survivors of childhood cancer.   
Authors of a study in Finland that included children and young adult cancer 
survivors (n = 13,860) who were diagnosed with cancer before 35 years old examined 
cardiovascular late effects among long-term survivors (Kero et al., 2014). Survivors who 
were diagnosed between 0 and 19 years of age showed a 13 times greater risk of 
developing cardiomyopathy/cardiac insufficiency and were three times more likely to 
experience myocardial infarction compared to their siblings. Survivors who had acute 
lymphoblastic leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, testicular 
malignancies, and CNS tumors demonstrated an increased risk of having cardiovascular 
problems (Kero et al., 2014). Even thirty years after cancer diagnosis, the cumulative 
incidences of cardiovascular problems continued in cancer survivors regardless of their 
age at cancer diagnosis (survivors who were either 0 to 19 or 20 to 34 years of age at 
cancer diagnosis) compared to their siblings (Kero et al., 2014). Thus, the 30-year 
cumulative incidence was about 2.5% for congestive heart failure, and less than 1% for 
cardiac ischemia in survivors of childhood cancer (Kero et al., 2014). The current study’s 
participants have survived an average of 25 years since cancer diagnosis, and the rate of 
cardiovascular problems in participants was 15%, which was higher than Kero and 
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colleagues’ findings. One area of further research could involve determining which 
diagnosis and what treatments contribute most to late effects and other subsequent 
negative outcomes for survivors. 
 Hypothesis C.   
Hypothesis C supported the notion that survivor membership in the subgroup with 
high physical symptoms and higher psychological symptoms was associated with poorer 
physical aspects of HRQOL. Details about these associations follow.  
 Symptom clusters and HRQOL. Survivors who were in the low symptom cluster 
group reported better physical and mental summary scores in HRQOL compared to 
survivors who were in the high symptom cluster group. The low symptom cluster group 
was chosen as a reference group since the number in this group was larger than that in the 
high symptom cluster group. The current study results related to other studies on 
symptom clusters among survivors of adult cancer.  
 Kim and colleagues identified several symptom clusters across time (Time 1, 
Time 2, and Time 3) in breast cancer patients who were undergoing chemotherapy or 
radiotherapy. Time 1 was prior to any treatments; Time 2 was within two days of 
treatments; and Time 3 was one month after completion of treatments (Kim et al., 2012). 
The researchers measured five psychoneurologic symptoms including depressed mood, 
cognitive disturbance, fatigue, insomnia, and pain. At Time 1, Kim and Beck identified 
four symptom subgroups including all low symptoms, high fatigue and low pain, high 
pain, and all high symptoms. In addition, the researchers examined the pattern of 
symptom clusters across time (Kim et al., 2012). In the current study, two groups were 
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identified: all high symptoms and all low symptoms. These categories were similar to 
those identified by Kim et al. In the current study, participants with higher physical 
symptoms showed higher psychological symptoms. In the current study, more types of 
symptoms were examined than in the Kim et al.’s study, including physical, psychosocial 
symptoms, and memory/learning symptoms, thus extending their findings.   
 Dodd and colleagues also examined symptom clusters and quality of life in breast 
cancer patients. Three time points were used: T1 (baseline-prior to treatment), T2 (end of 
cancer treatment), and T3 (about one year after at the start of chemotherapy) (Dodd et al., 
2010). The researchers categorized the participants into four subgroups: all low 
symptoms, mild symptoms, moderate symptoms, and all high symptoms. The mild 
symptoms subgroup had mild fatigue and pain, and the moderate subgroup had a 
moderate level of pain, fatigue, sleep disturbance, and depression. Although each 
subgroup showed a distinctive category of symptoms across time, some of the subgroups 
included a small sample size. For example, at Time 1, the participants with mild 
symptoms included five participants; at Time 3, no one reported all low symptoms, and 
only three participants reported all high symptoms (Dodd et al., 2010). Identifying fewer 
than four subgroups might better explain symptoms at each time point. In the current 
study, a person-centered approach was used, which allowed each cluster to include 
subgroups of patients who share similar patterns of symptom experience. Each group 
included a substantial sample size, nearly 900 for the high symptom cluster group and 
nearly 2,200 for the low symptom cluster group. In order to meaningfully explain each 
cluster’s characteristics, it is important to have sufficient sample size in each cluster.    
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In Dodd et al.’s study, participants who belonged to the “mild” and “moderate” 
subgroups reported significantly higher HRQOL scores compared to the “moderate” or 
“all high” subgroups (Dodd et al., 2010). This is similar to the current study findings that 
the high symptom cluster’s members reported poorer HRQOL than those in the low 
symptom cluster. Dodd et al.’s study had three time points: T1 (before treatment), T2 
(end of treatment), and T3 (one year after the first treatment). Interestingly, nearly a 
majority of participants (90%) remained in the mild symptom clusters at Time 2 and 
Time 3 in their study. This suggests that symptoms can have persistent effects to at least 
one year after cancer treatment.  
Although the current study had at least five time points of data collection 
associated with the longitudinal design, only the T1 time point was examined for this 
project. For future research, important information might be gleaned by examining the 
data longitudinally to understand whether participants experienced similar symptoms 
across time and to clarify the symptom cluster effects on HRQOL in these survivors 
across time. This information could be critical in the development of survivorship plans 
for childhood cancer survivors. 
Demographic, clinical variables, and HRQOL. Children with cancer might 
experience several symptoms related to their cancer or cancer-related treatment (Baggott, 
Dodd, Kennedy, Marina, & Miaskowski, 2009; Hockenberry & Hooke, 2007). These 
symptoms could impact the child’s quality of life (Baggott et al., 2009). In the current 
study, several demographic factors were associated with poorer physical HRQOL. These 
variables were survivors who were older when they took the survey (more than 40 years), 
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had a lower educational level (less than high school diploma), were unemployed, and had 
lower annual personal income (less than $19,999).  
In another study using CCSS data, survivors who were female, older at the time of 
survey, obese, living in a household with a lower income level (less than $20,000), were 
treated with alkylating agents, or were disfigured reported poorer physical HRQOL 
(Nolan et al., 2014). Researchers found that younger age at cancer diagnosis, such as less 
than 10 years old, was associated with poorer physical and mental HRQOL (Maurice-
Stam et al., 2009; Mertens et al., 2014; Nathan et al., 2007; Ness et al., 2010). The “age at 
cancer diagnosis” variable was not included in multivariable analysis in the current study 
because the age at the survey and time after cancer diagnosis were related to the age of 
cancer diagnosis. Thus, several demographic variables were identified to have an impact 
on HRQOL in long-term survivors of childhood cancer.  
In the current study, several clinical factors were associated with poorer physical 
HRQOL. Treatment variables (e.g., types of chemotherapy, types of radiotherapy) were 
used in the multivariable analysis in this study but type of cancer was not included in this 
analysis. These treatment variables are closely related to types of cancer, and use of these 
two variables at the same time could have resulted in multicollinearity problems. The use 
of platin drugs (cisplatin/carboplatin/oxaliplatin) was associated with poorer physical 
HRQOL. Being treated with muscle radiotherapy (with the exception of head/neck, 
chest/lung, pelvis/abdominal/urinary, and the reproductive area) was associated with 
poorer physical HRQOL. According to a literature review by Robinson and Carr, the 
medications cisplatin, carboplatin, and oxaliplatin were considered as contributing to high 
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and moderate emetic problems (Robinson & Carr, 2007). Children who experience 
vomiting might have electrolyte imbalances, dehydration, and weight loss (Robinson & 
Carr, 2007). Thus, use of platin drugs has the consequence of emetic problems in children 
with cancer and this could result in their poorer physical HRQOL.  
There are other clinical factors that affect cancer survivors’ physical HRQOL. In 
a study of 643 survivors of childhood cancer in Italy, survivors who were diagnosed with 
a CNS tumor were found to be 2.5 times more likely to report poorer HRQOL scores 
compared to survivors who were diagnosed with leukemia (Alessi et al., 2007). In 
addition, female survivors were more likely to report poorer HRQOL compared to male 
survivors. Survivors who were diagnosed with bone tumors, CNS tumors, and both 
Hodgkin disease and neuroblastoma were 18 times, three times, and two times more 
likely, respectively, to report ambulation problems compared to survivors who had 
leukemia (Alessi et al., 2007). In future work, it will be important to have separate 
analyses for male and female survivors to better understand gender effects related to 
HRQOL outcomes as this too could be important information for the development of 
survivorship plans for different groups of survivors.  
In the current study, the relationship between symptom clusters and HRQOL were 
examined. Huang and colleagues’ study examined the relationship between each 
symptom and HRQOL (Huang et al., 2013). All of the symptoms explained 60% of 
HRQOL, but demographic and clinical variables explained 15% of HRQOL in long-term 
survivors of childhood cancer (Huang et al., 2013). Symptoms seem to have more effect 
on HRQOL than sociodemographic factors. In Huang and colleagues’ study as well as in 
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the current study, more symptom experiences were associated with poorer HRQOL. In 
future studies, researchers could determine whether to examine symptoms separately or 
use clusters based on their research purposes to better understand the relationship 
between these and patients’ outcomes.  
In the current study, survivors who were female, who had less education (less 
than a high school diploma), were unemployed, and unmarried reported poorer mental 
HRQOL. On the other hand, survivors who were treated with chemotherapy 
(cisplatin/carboplatin/oxaliplatin) or alkylating agents reported better psychosocial 
HRQOL. This might be related to the social supports they received as caregivers worked 
with them to help decrease the side effects of chemotherapy. As previously mentioned, in 
the current study, the two types of chemotherapy examined were highly emetic 
chemotherapies, and these drugs result in more than 90% of emetic problems (e.g., 
nausea, vomiting) (Robinson & Carr, 2007). However, there are few studies to examine 
the relationship between platin drugs and HRQOL. This is in need of further study. In the 
current study, radiotherapy did not affect mental HRQOL. However, in another study 
using CCSS data, survivors of adolescent cancer, other than non-Hispanic Whites, and 
survivors who had disfigurement in the head/neck area, reported statistically significantly 
poorer mental HRQOL (Nolan et al., 2014). In summary, in the current study, several 
demographic and clinical predictors were associated negatively or positively with 
physical and mental HRQOL in survivors of childhood cancer.  
 It is hypothesized that there are subgroup membership differences in physical and 
mental HRQOL. In the current study, the mean of physical HRQOL and the mean of 
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mental HRQOL were lower compared to the mean of physical and mental HRQOL in 
survivors who were in the high symptom cluster group. Using the same SJLIFE cohort 
data, Huang and colleagues examined HRQOL and symptoms in 1,667 adult survivors of 
childhood cancer (Huang et al., 2013). Huang and colleagues’ study included survivors 
who attended a follow-up visit after being surveyed for the SJLIFE cohort study (not the 
same as the SJLIFE data used in the current study). In their study, survivors who 
experienced more symptoms reported poorer physical component summary scores (PCS) 
and mental component summary (MCS) scores in HRQOL. However, this study did not 
identify symptom clusters and symptoms that negatively affected HRQOL. This is similar 
to the current study’s findings.  
Researchers have used various cutoff scores to determine poor HRQOL. Two 
researchers used 40 (on the same instrument) as the cutoff score (Hudson et al., 2003; 
Zeltzer et al., 2008), whereas Norman et al. used 45 as the cutoff score to determine 
poorer PCS HRQOL as well as MCS HRQOL (Norman, Sloan, & Wyrwich, 2003). In 
the current study, when 40 was used as the cutoff score indicating poor HRQOL, the high 
symptom cluster group had slightly higher mean physical HRQOL and lower mean 
mental HRQOL. This suggests that survivors belonging to the high symptom cluster 
group reported poorer physical HRQOL and poorer mental HRQOL. In the low symptom 
cluster group, the mean physical HRQOL scores were higher than the cutoff score, which 
is 40, and the mental HRQOL scores were higher than the cutoff score, also 40. This 
suggests that survivors who are in the low symptom cluster group reported better physical 
and mental HRQOL. In another study, using CCSS data, researchers found that the 
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physical component summary HRQOL was 51.6 and mental component summary 
HRQOL was 41.4 for 674 female survivors of childhood cancer, and they found that 
physical summary scores were 53.2 and mental summary scores were 48.8 from 629 male 
survivors of childhood cancer (Maunsell et al., 2006). In both domains of HRQOL, males 
reported higher HRQOL than female survivors. It might be necessary to examine the 
effects of gender on HRQOL in long-term survivors of childhood cancer in a future 
study.  
Hypothesis D.   
The findings of this study supported the notion that subgroup membership has 
moderating effects between demographics/clinical variables and HRQOL. Details about 
these associations follow. There were moderating effects of symptom clusters between 
four variables and HRQOL. No prior studies have examined symptom clusters and 
moderating effects of subgroup membership between predictors and patient outcomes. 
Thus, the current study’s findings were not compared with other studies regarding 
moderating effects. In the current study, when survivors had lower than a high school 
diploma and belonged to the high symptom cluster group, they had poorer physical 
HRQOL compared to survivors who were in the low symptom cluster group. Also, 
regarding treatment with alkylating agents, those in the high symptom cluster group had 
poorer physical HRQOL than those in the low symptom cluster group. Regarding mental 
HRQOL, unemployed survivors who were in the high symptom cluster had poorer mental 
health than those in the other cluster. Even with the same demographic characteristics or 
treatment variables, survivors in the high symptom cluster group reported poorer physical 
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and mental HRQOL. Future research is necessary to examine the mediating effects of 
symptom clusters and predictors in this population. Also, it is necessary to provide 
nursing interventions for survivors in the high risk group in order to improve both their 
physical and mental HRQOL.  
Application of the Dynamic Symptoms Model   
 The Dynamic Symptoms Model (Brant et al., 2016) represents the hypothesized 
relationship between antecedents, symptoms, and outcomes. This theory also considers 
the levels of symptom experience and appraisal of symptoms. The current study found 
that there were significant relationships between sociodemographic factors, clinical 
factors, symptoms, and outcomes among survivors of childhood cancer. Overall, an 
antecedent directly affects a symptom experience or quality of life. In addition, an 
antecedent indirectly affects quality of life through the symptom experience. For 
example, the HRQOL status was different based on each symptom cluster group.  
Considering antecedents, most demographic factors including age, gender, 
income level, and education were associated with the symptom experience. In addition, 
under the physiologic antecedent category, medical conditions (type of cancer), 
treatments, and comorbidities were associated with the higher symptom cluster group. In 
the current study, the existence of ten symptoms (yes or no) was used, and there was no 
information about the intensity of symptom or quality of symptoms. The consequences of 
the symptoms, such as quality of life, were different based on each symptom cluster. For 
example, an individual who belongs to the high symptom cluster group reported lower 
levels of physical and psychological HRQOL. To better understand the relationship 
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between antecedents and symptoms, it would be useful to have more information about 
treatment variables, such as using accumulative doses of treatments (e.g., chemotherapies 
or radiotherapies). Other antecedents, under the physiological, social, and spiritual or 
environmental categories, and their relationship to quality of life were not tested since 
these variables were not available in the current data set. However, future studies might 
test whether an individual's knowledge, values, coping skills, self-care, or cultural 
differences impact the individual’s symptom experience or quality of life. 
The existence of the symptom experience was used for this analysis, but use of 
additional characteristics of symptoms (e.g., temporality, intensity, quality, distress, and 
appraisal) could provide useful information related to HRQOL. For example, intensity of 
symptom, appraisal of symptoms, and symptom changes across time could provide 
detailed information that would be useful to guiding providers in care planning and for 
the development of survivorship care plans that could be tailored to the unique needs of 
the individual cancer survivor. Also, further study about the nuances of the associations 
of the various aspects of the model (antecedents, symptom experience, and quality of life) 
and survivor outcomes might provide more useful information to guide symptom 
management interventions.  
This was a preliminary study using the dynamic symptoms model (Brant et al., 
2016) as a way of understanding the symptom experience of childhood cancer survivors 
and associated long-term outcomes. This model is useful for understanding the 
relationships and trajectories from antecedents to symptoms to outcomes for survivors. 
However, in the future, this model might be further tested considering various 
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antecedents, symptom experiences, symptom trajectory, and symptom management 
interventions.  
Limitations 
 Several limitations of this study should be noted. A cross-sectional design was 
used for the current study. This strategy did not allow for the explanation of the 
inferential relationships between predictors, symptoms, and HRQOL. Although the 
original SJLIFE data had five different time points, only the first time point of data was 
used for the current analysis. This choice was made because the first time point of data 
had the largest sample size, and it was necessary to preliminarily explore the relationships 
between symptom clusters and HRQOL in survivors of childhood cancer before 
examining data longitudinally. The Dynamic Symptoms Model was used as a theoretical 
framework, but symptom intensity and quality were not examined because that 
information was not available in the primary data set. Since the clinical factors were 
binary variables, the accumulative doses of chemotherapy or radiotherapy were not 
tested, which if available might have yielded detailed information about the effect of 
treatment variables for the individuals who were in the high symptom cluster group. This 
could be important information for treatment providers in designing the most effective 
treatment plan with the lowest incidence of poor outcomes for the survivor. 
Regarding analysis, cluster analysis is an exploratory statistical procedure that 
requires researchers to make decisions about the number of clusters and names of the 
symptom clusters (Miaskowski et al., 2006). Although empirical guidelines were used to 
choose the best-fit model, a greater or lesser number of symptom clusters could have 
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explained the symptoms more accurately. The current sample is limited to survivors who 
were mostly middle-aged, non-Hispanic Whites, with a high level of educational 
attainment in the United States, which might be hard to generalize to childhood cancer 
patients who are from minority groups, of other races/ethnicities, and for those of lower 
education levels in developing countries. For future research, it might be helpful to 
examine a homogeneous survivor sample that is characterized by the same types of 
cancer, same types of treatment, and similar age at cancer diagnosis in order to identify 
more distinctive subgroups.  
Implications 
 Implications for Research.  
This study used a new statistical approach to identify symptom clusters 
experienced by survivors of childhood cancer. The larger sample from SJLIFE data 
allowed the use of clinically relevant variables within the latent class analysis (LCA) 
using mixture modeling to identify distinct symptom subgroups. A cross-sectional design 
was used for the current project. However, approximately 50% of SJLIFE participants 
have completed the HRQOL survey at more than two time points. In a future study it will 
be important to conduct longitudinal analyses to better understand the relationship of 
cancer treatments, symptoms, cluster membership and outcomes so as to better inform 
care planning for these survivors. Using a longitudinal design could provide further 
information for the development of survivorship plans.  
The current study includes long-term survivors of childhood cancer, but future 
research might include those in various stages of cancer treatment, such as those 
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undergoing cancer treatment or shortly following completion of cancer treatment. 
Understanding symptom clusters in each stage of cancer treatment could provide 
information for researchers about designing symptom management interventions for the 
target group in a particular cluster, for example, the high symptom cluster. Childhood 
cancer survivors who were diagnosed with cancer between 0 to 19 years of age were used 
for data analysis in order to examine symptom clusters and HRQOL. However, it is 
possible that encompassing childhood and adolescence into one study group might mask 
the unique developmental differences of survivors of adolescent cancer. Although the age 
at cancer diagnosis was categorized into three different groups, this variable was not used 
in a multivariable analysis to avoid multicollinearity with time since cancer diagnosis. 
For future research, it may be necessary to examine symptom clusters and HRQOL in 
different age groups such as survivors of adolescent cancer.  
 Implications for Nursing Practice. 
This study had a substantial sample size of participants. The heterogeneous cancer 
diagnoses, types of chemotherapy, and types of radiotherapy make the findings 
potentially generalizable for other childhood cancer survivors and patients. Findings from 
this study can provide the basis for investigation into the stability of clusters with 
survivors from different socio-economic groups, different types of cancer, and those who 
received different types of chemotherapies and radiotherapies.  
Nurses need to pay attention to patients who experience high degrees of physical 
and mental symptoms associated with their cancer and treatments because these patients 
risk having a poor quality of life as a result. In the current study, most long-term 
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survivors of childhood cancer experience pain and disfigurement, and these 
complications are associated with poorer HRQOL. Also, a subgroup of participants 
experienced psychological symptoms including anxiety, depression, and somatization. In 
particular, survivors of brain tumors experienced poorer HRQOL compared to survivors 
of leukemia. Nurses need to be aware of and understand these symptoms and target 
populations who might have poorer health outcomes in order to provide effective nursing 
care. These study findings can help health care providers make tailored survivorship care 
plans for childhood cancer patients. Nurses need to consider nursing interventions 
designed to decrease treatment complications during cancer treatment. Also, it is 
important to provide resources to survivors such as counseling with mental health care 
providers, support groups with other cancer patients, and writing or music therapy to aid 
in the relief of psychological distress. These could all be in the form of a comprehensive 
survivorship care plan.  
 Implications for Clinicians. 
This study included survivors who had received eight different types of 
chemotherapy and five different body areas of radiotherapy. Understanding the 
differential effects of treatment-related variables could help clinicians understand that 
when their patients have received certain types of chemotherapy and certain body areas 
of radiotherapy, they may be at a greater risk for being in a high symptom cluster, which 
could lead to poorer outcomes. Also, helping clinicians understand that symptoms often 
co-occur, and that physical and mental symptoms may be associated with each other, 
could aid these caregivers in providing the best treatments/interventions for their young 
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patients. For example, when a patient is in a cluster with more severe symptoms, 
clinicians might need to assess the prevalence of other symptoms in the same cluster. 
Also, clinicians could include family and friends as resources in the survivorship care 
plans in order to support survivors of childhood cancer to cope with cancer. Clinicians’ 
insights and comprehensive assessments, as well as targeted interventions, could prevent 
or decrease symptoms for cancer patients, which could in turn result in improved 
outcomes for these survivors over their lifetime.  
Conclusion  
This study focused on the identification of symptom clusters and HRQOL in 
survivors of childhood cancer. Two distinctive subgroups were identified based on 
symptom experience. The mixture modeling was useful for identifying the subgroups. 
Using advanced statistical analysis such as mixture modeling with a person-centered 
approach helped in the identification of a high symptom cluster and a low symptom 
cluster. This statistical approach could be replicable for future studies that may involve 
identifying symptom clusters in various types of cancer or other types of illnesses.  
In the current study, each subgroup shared unique common symptoms. Each 
subgroup had distinctive sociodemographic and clinical characteristics that were 
antecedent to the clusters and distinctive health outcomes. Survivors of childhood cancer 
who were in the high symptom cluster group experienced poorer physical and mental 
HRQOL outcomes. Findings from this person-centered approach to analysis provided 
clinically useful insights for health care providers and could lead to the development of 
symptom management interventions for the high-risk group that could help those in this 
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group to have better health outcomes. Future study should continue to identify factors 
that are related to symptom experiences and HRQOL for survivors of childhood cancer 
who are in the various cancer survivorship periods. This could lead to the design and 
testing of interventions to decrease symptoms and to increase HRQOL for these 
populations. 
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